Nucleic acid molecule, recombinant baculovirus containing same and application thereof
By discovering new exogenous fragment insertion sites on the baculovirus genome and designing tail-to-tail gene pairs, combining AAV packaging elements, the instability of exogenous genes in the BEV genome is solved, and the exogenous genes are realized Long-term stable passage and efficient expression.
Patent Information
- Application Number
- CN202411104315.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-17
- Publication Date
- 2024-11-15
AI Technical Summary
In the traditional recombinant baculovirus expression system, the instability of exogenous genes in the BEV genome leads to a decrease in expression, and defect interference viruses have the advantage, affecting the long-term stable passage of exogenous genes.
By discovering new exogenous fragment insertion sites on the baculovirus genome, insertion of exogenous fragments does not affect viral replication and passivation stability, it provides a new effective insertion site for the BEV genome, using tail-to-tail gene pairs and non-coding regions. The design of the recombinant baculovirus is constructed by combining select marker genes and target genes, including AAV packaging essential elements such as Cap, Rep and ITR genes.
Long-term stable passage of exogenous genes has been achieved, the stability and compatibility of the expression system of recombinant baculoviruses have been improved, and the target proteins can be produced efficiently.
Smart Images

Figure CN118956967A_ABST
Abstract
Description
[0001] This application is a divisional application with application number 202410459550.3, application date April 17, 2024, and invention name “Nucleic acid molecules, recombinant baculovirus containing the same and their applications”. Technical Field
[0002] The present application belongs to the field of biomedicine, and specifically relates to a modified virus vector technology, and in particular to a nucleic acid molecule, a recombinant baculovirus containing the same, and applications thereof. Background Art
[0003] The insect cell expression system (i.e., recombinant baculovirus expression system) is a eukaryotic expression system that can express foreign genes from a variety of species, including fungi, bacteria, viruses, and plants, in insect cells. The insect cell expression system has the advantages of high recombinant protein expression, comprehensive protein post-translational modification, suitability for large-scale production, and low production costs. It has been widely used in the expression of a variety of recombinant proteins, drug research and development, and the production of commercial biological products such as drugs and vaccines.
[0004] In the traditional recombinant baculovirus expression system, the Bac-to-Bac system is widely used. The earliest developer of this system, Luckow et al., selected the polyhedron gene (polh) site of the baculovirus replication non-essential gene as the recombination site of the Tn7 transposon. The insertion of foreign genes into this gene site can usually achieve a high expression level (Luckow et al., 1993, J. Virol. 67 (8): 4566-4579). Studies have reported that during the passage of BEV in the insect baculovirus expression system, defective interfering viruses with some genes missing will be generated. The defective interfering viruses gradually occupy a proportional advantage during the passage, resulting in a decrease in the expression of foreign genes (Pijlman et al., J Gen Virol, 2003, 84: 2041-2049). The unstable factors of exogenous genes in the BEV genome include the instability of the exogenous genes themselves, the insertion of DNA fragments, the insertion site, and the selectivity of different cell environments for defective viruses (Willemsen et al., Virus Evol, 2019, 5(2): vez045). Studies have reported that when the Tn7 transposon in the Bac to Bac system is replaced from the original polh site to the new insertion site odv-e56 locus, the obtained BEV can highly express exogenous genes. It is particularly noteworthy that the stability of the BEV continuous passage is significantly enhanced (Pijlman et al., J Gen Virol, 2003, 84: 2669-78). In addition, studies have shown that the traditional shuttle plasmid-based baculovirus system, which simultaneously accommodates the Rep gene, Cap gene and ITR core expression elements on the shuttle plasmid, has poor stability. The highly integrated recombinant baculovirus BEV can only be stably propagated for 4 generations. After the 5th generation, the yield of BEV to prepare rAAV will be significantly reduced (see Yang et al., 2018, Mol Ther Methods Clin Dev. 2018 Jul 4; 10: 38-47.).
[0005] In view of the above background, in order to achieve long-term stable propagation of inserted exogenous genes, it is still necessary to screen effective insertion sites in the new BEV genome. Summary of the invention
[0006] Based on this, one or more embodiments of the present application provide a nucleic acid molecule, a recombinant baculovirus containing the same, and applications thereof. The technical solution includes:
[0007] One or more embodiments of the present application provide a nucleic acid molecule, the nucleic acid molecule comprising: a nucleic acid fragment 1, a nucleic acid fragment 2, and an exogenous gene expression frame for expressing an exogenous fragment located between the nucleic acid fragment 1 and the nucleic acid fragment 2;
[0008] The complementary fragments of the nucleic acid fragment 1 and the nucleic acid fragment 2 are a tail-to-tail gene pair;
[0009] The nucleic acid fragment 1 and the nucleic acid fragment 2 are connected to a non-coding region, the 5' end of the non-coding region is taa and the 3' end is tta, and the exogenous fragment is inserted between taa and tta.
[0010] In some embodiments of the present application, the sequence of the non-coding region is taatta, and the exogenous fragment is inserted between taa and tta.
[0011] In some embodiments of the present application, the length of the sequence of the non-coding region is 7 bp-200 bp.
[0012] In some embodiments of the present application, the tail-to-tail gene pair is from a baculovirus.
[0013] In some embodiments of the present application, the tail-to-tail gene pair is from any of the following baculoviruses:
[0014] Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudococcidae multinucleocapsid nuclear polyhedrosis virus, Gypsy moth multinucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multinucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus and Spodoptera litura nuclear polyhedrosis virus.
[0015] In some embodiments of the present application, the tail-to-tail gene pair is from Autographa californica nuclear polyhedrosis virus.
[0016] In some embodiments of the present application, the tail-to-tail gene pairs are both baculovirus conserved genes.
[0017] In some embodiments of the present application, the exogenous fragment includes one or more of a selectable marker gene and a target gene.
[0018] In some embodiments of the present application, the target gene includes an AAV packaging essential element, and the AAV packaging essential element includes one or more of a Cap gene, a Rep gene, and an ITR gene;
[0019] In some embodiments of the present application, a GOI is inserted between the left ITR segment and the right ITR segment of the ITR gene.
[0020] In some embodiments of the present application, the exogenous gene expression frame includes a promoter that regulates the selection marker gene, including a baculovirus very early promoter.
[0021] In some embodiments of the present application, the exogenous gene expression frame includes a promoter that regulates the target gene, including a P10 promoter or a PH promoter.
[0022] In some embodiments of the present application, the selection marker gene includes one or more of a luciferase gene, a neomycin resistance gene, a hygromycin phosphotransferase gene, a dihydrofolate reductase gene, a thymidine kinase gene, a glutamine synthetase gene, an asparagine synthetase gene, a tryptophan synthetase gene, a histidinol dehydrogenase gene, an aminoglycoside phosphotransferase gene, and a tryptophan synthetase gene.
[0023] In some embodiments of the present application, the selection marker gene is a luciferase gene.
[0024] In some embodiments of the present application, the target gene encodes one or more of an antibody, a polypeptide, an enzyme, a hormone, a growth factor and a receptor.
[0025] In some embodiments of the present application, the tail-to-tail gene pair includes any one of the following gene pairs:
[0026] Gene pair 1 is the lef4 gene and the orf91 gene, and the corresponding insertion site is denoted as the OB1 site;
[0027] Gene pair 2 is the p15 gene and the cg30 gene, and the corresponding insertion site is recorded as the OB2 site; and,
[0028] Gene pair 3 is the env-prot gene and the pkip gene, and the corresponding insertion site is recorded as the OB3 site. In some embodiments of the present application, the sequence of the non-coding region includes the sequence shown in SEQ ID NO.1.
[0029] In some embodiments of the present application, the sequence of the nucleic acid molecule is as shown in SEQ ID NO.44 at 2779bp to 4912bp, SEQ ID NO.46 at 2779bp to 11984bp, SEQ ID NO.47 at 2779bp to 8988bp, SEQ ID NO.48 at 2903bp to 8875bp, SEQ ID NO.49 at 2861bp to 8881bp, SEQ ID NO.50 at 749bp to 4910bp, SEQ ID NO.52 at 749bp to 4776bp, or SEQ ID NO.53 at 2903bp to 6930bp.
[0030] One or more embodiments of the present application also provide a recombinant plasmid, which includes the nucleic acid molecule.
[0031] In some embodiments of the present application, the recombinant plasmid comprises a shuttle plasmid.
[0032] In some embodiments of the present application, the recombinant plasmid is shown as SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.
[0033] One or more embodiments of the present application also provide a recombinant baculovirus, the genome of which includes the nucleic acid molecule.
[0034] In some embodiments of the present application, the recombinant baculovirus includes Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudococcidae multiple nucleocapsid nuclear polyhedrosis virus, Gypsy moth multiple nucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multiple nucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus or Spodoptera litura nuclear polyhedrosis virus.
[0035] In some embodiments of the present application, the genome contains a deletion of one or more of the Chia gene and the Cath gene.
[0036] In some embodiments of the present application, other loci of the genome of the recombinant baculovirus are inserted with exogenous fragments as defined above.
[0037] In some embodiments of the present application, the selection marker gene is inserted into any one of the OB1 site, the OB2 site and the OB3 site.
[0038] One or more embodiments of the present application also provide a method for constructing the recombinant baculovirus, the method comprising the following steps:
[0039] causing homologous recombination between the donor plasmid and the baculovirus genome, thereby constructing a recombinant baculovirus;
[0040] The donor plasmid comprises the nucleic acid molecule.
[0041] In some embodiments of the present application, the recombinase used in homologous recombination includes RED recombinase, Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.
[0042] In some embodiments of the present application, the donor plasmid comprises a shuttle plasmid.
[0043] In some embodiments of the present application, the donor plasmid is shown as SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.
[0044] One or more embodiments of the present application also provide an adeno-associated virus packaging vector system, which includes AAV packaging essential elements, wherein the AAV packaging essential elements include one or more of the Cap gene, the Rep gene and the ITR gene; the AAV packaging essential elements are located in the same or different nucleic acid molecules.
[0045] In some embodiments of the present application, a GOI is inserted between the left ITR segment and the right ITR segment of the ITR gene.
[0046] One or more embodiments of the present application also provide a method for producing an expression product of an exogenous fragment, the production method comprising the following steps:
[0047] The host cells are infected with the recombinant baculovirus and then cultured, and the expression product of the exogenous fragment is separated from the obtained culture product.
[0048] In some embodiments of the present application, the host cell comprises an insect cell line.
[0049] In some embodiments of the present application, the insect cell line comprises a Lepidoptera insect cell line.
[0050] In some embodiments of the present application, the lepidopteran insect cell line includes a Spodoptera frugiperda cell line, a Bombyx mori cell line or a Trichoplusia ni cell line.
[0051] In some embodiments of the present application, the lepidopteran insect cell line includes an ovarian tissue cell line or a fat body cell line.
[0052] In some embodiments of the present application, the production method further comprises the step of detecting the titer of the obtained recombinant baculovirus.
[0053] In some embodiments of the present application, the titer of the obtained recombinant baculovirus is detected by a standard curve method, comprising the following steps:
[0054] Providing a standard curve, wherein the standard curve reflects the linear relationship between the luciferase activity value and the virus titer value; and,
[0055] Detecting the activity value of luciferase expressed by the luciferin gene in the recombinant baculovirus to be tested, substituting it into the standard curve, and calculating the virus titer value of the recombinant baculovirus to be tested;
[0056] The activity value of the luciferase = the luminescence intensity value generated by the luciferase expressed by the recombinant baculovirus - the luminescence intensity value of the virus-free control substance.
[0057] One or more embodiments of the present application also provide a method for producing a recombinant adeno-associated virus or a GOI expression product, wherein the production method uses the adeno-associated virus packaging vector system.
[0058] Compared with the traditional technology, the beneficial effects of this application include:
[0059] The present application discovered new insertion sites for exogenous fragments on the baculovirus genome. Insertion of exogenous fragments at these insertion sites does not affect baculovirus replication and is stable in propagation, providing new options for effective insertion into the BEV genome in the baculovirus expression system. BRIEF DESCRIPTION OF THE DRAWINGS
[0060] In order to more clearly illustrate the technical solutions in the embodiments of the present application and to more completely understand the present application and its beneficial effects, the following is a brief introduction to the drawings required for the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application, and those skilled in the art can obtain other drawings based on these drawings without creative work.
[0061] Figure 1 Schematic diagram of the recombinant baculovirus genome in the embodiment of the present application; wherein: the left side is a schematic diagram of the recombinant bacmid genome of AcMNPV, and the baculovirus AcMNPV genome is a double-stranded circular DNA with a total length of 133,894 bp;
[0062] Figure 2 The electrophoresis diagram of the products of PCR identification of pKD46 / DH10Bac competent cells in Example 1;
[0063] Figure 3 This is the electrophoresis diagram of PCR identification of ΔCC-DH10Bac competent cells in Example 1;
[0064] Figure 4 This is the electrophoresis diagram of PCR identification of pKD46 / ΔCC-DH10Bac competent cells in Example 1;
[0065] Figure 5 The schematic diagram of the genome of R0329 {rBEV-GLuc(OB1)-8KC-EGFP(Tn7)} constructed in Example 1;
[0066] Figure 6 The schematic diagram of the genome of R0330{rBEV-8KC-EGFP(OB1)} constructed in Example 2;
[0067] Figure 7 The schematic diagram of the genome of R0331{rBEV-8KC(OB1)-EGFP(Tn7)} constructed in Example 4;
[0068] Figure 8 This is a schematic diagram of the genome of R0332 {rBEV-8KC (OB1)} constructed in Example 5;
[0069] Fig. 9 This is a schematic diagram of the genome of R0004{rBEV-EGFP(Tn7)} constructed in Example 6;
[0070] Fig.10 This is a schematic diagram of the genome of R0333{rBEV-8KC(OB2)} constructed in Example 7;
[0071] Fig.11 The schematic diagram of the genome of R0334{rBEV-8KC(OB2)-EGFP(Tn7)} constructed in Example 8;
[0072] Fig.12 This is a schematic diagram of the genome of R0335{rBEV-8KC(OB3)} constructed in Example 9;
[0073] Fig.13 The schematic diagram of the genome of R0336{rBEV-ITR-EGFP(OB3)} constructed in Example 10;
[0074] Fig.14 The schematic diagram of the genome of R0337{rBEV-8KC(OB1)-ITR-EGFP(OB3)} constructed in Example 11;
[0075] Fig.15 The fluorescence photographs of each generation of R0330{rBEV-8KC-EGFP(OB1)} in Example 2, R0336{rBEV-ITR-EGFP(OB3)} in Example 10, and R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)} in Example 11 expanded to P7 at fixed inoculation starting density and inoculation MOI;
[0076] Fig.16 For the correlation analysis of the recombinant baculovirus luciferase activity-titer in Example 13, a standard curve formed by the log value of the titer of the standard and the RLU value, R 2=0.9845;
[0077] Fig.17 The results of the staining of the purified finished viruses of each recombinant baculovirus system model in Example 14, lane 1 is R0329-AAV8-EGFP in Example 1, lane 2 is R0330-AAV8-EGFP in Example 2, lane 3 is R0331-AAV8-EGFP in Example 4, lane 5 is R0334-AAV8-EGFP in Example 8, lane 6 is R0335-AAV8-EGFP in Example 9, and lane 6 is R0336-AAV8-EGFP in Example 10. The titer of the finished virus purified from the initial mixed solution of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10 is low, and only light shadows can be seen for VP1 and VP2;
[0078] Fig.18 These are the staining results of the purified finished viruses in Example 3. Lane 1 is R0338-AAV9-EGFP, lane 2 is R0339-AAV5-EGFP, and lane 3 is R0340-AAV2-EGFP. The titer of the finished virus purified from the initial mixed solution of R0338-AAV9-EGFP is low, and VP1 / VP2 is not obvious. DETAILED DESCRIPTION
[0079] The present application will be further described in detail below in conjunction with the accompanying drawings, embodiments and examples. It should be understood that these embodiments and examples are only used to illustrate the present application and are not used to limit the scope of the present application. The purpose of providing these embodiments and examples is to make the understanding of the disclosure of the present application more thorough and comprehensive. It should also be understood that the present application can be implemented in many different forms, is not limited to the embodiments and examples described herein, and those skilled in the art can make various changes or modifications without violating the connotation of the present application, and the equivalent form obtained also falls within the protection scope of the present application. In addition, in the description below, a large number of specific details are given in order to provide a more comprehensive understanding of the present application, and it should be understood that the present application can be implemented without one or more of these details.
[0080] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing implementation modes and embodiments and are not intended to limit this application.
[0081] the term
[0082] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0083] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").
[0084] In the present application, "plurality", "multiple", "multiple times", "multiples", etc., unless otherwise specified, refer to a number greater than 2 or equal to 2. For example, "one or more" means one or greater than or equal to two.
[0085] As used herein, "combination thereof", "any combination thereof", "any combination thereof" etc. include all suitable combinations of any two or more of the listed items.
[0086] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc., shall be based on the ability to implement the technical solution of this application, solve the technical problems of this application, and achieve the expected technical effects of this application.
[0087] Herein, “preferred”, “better”, “more preferred” and “suitable” are merely used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute limitations on the scope of protection of this application.
[0088] In the present application, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.
[0089] In this application, "optionally", "optional", and "optional" mean optional or dispensable, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent.
[0090] In the present application, the terms "first", "second", "third", "fourth", etc. in "the first aspect", "the second aspect", "the third aspect", "the fourth aspect", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.
[0091] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0092] In the present application, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In this article, it is equivalent to directly listing each integer, such as t is an integer selected from 1 to 10, indicating that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.
[0093] The temperature parameters in this application, unless otherwise specified, are allowed to be either constant temperature treatment or to vary within a certain temperature range. It should be understood that the constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuations within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.
[0094] In the present application, % (w / w) and wt% both represent weight percentage, % (v / v) refers to volume percentage, and % (w / v) refers to mass volume percentage.
[0095] All documents mentioned in this application are cited as references in this application, just as each document is cited as reference separately. Unless they conflict with the application purpose and / or technical solution of this application, the cited documents involved in this application are cited with all contents and all purposes. When the cited documents are involved in this application, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the cited documents are involved in this application, the examples and preferred methods of the cited relevant technical features can also be incorporated into this application as references, but are limited to the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, the present application shall prevail or be modified adaptively according to the description of this application.
[0096] Locus (locus, loci) is also called seat. The position of a gene on a chromosome. At the molecular level, it is a DNA fragment with genetic effects. A locus can be a gene, a part of a gene, or a DNA fragment with some regulatory effect. A locus is different from a site, which is a mutation position within a cistron and can be as small as a nucleotide pair.
[0097] Infectious titer refers to the concentration of viral particles that can transduce cells. Infectious titer is usually quantified by cell transduction assay. Studies have shown that the ratio of rAAV physical titer to infectious titer is about 50:1 (Zeltner et al., 2010).
[0098] TCID50, half tissue culture infectious dose, also known as 50% tissue cell infection dose, refers to the amount of virus required to cause half of the cells to become cytopathic or die (cytopathic effect, CPE) in the wells of a culture plate or test tube, and is used to characterize the titer of the virus.
[0099] Tail-to-tail gene pairs refer to two adjacent genes in a genomic region that are located on two different strands of DNA and are transcribed in opposite directions.
[0100] Gene Expression Box is a biological concept that contains the DNA sequence required for gene expression for a specific purpose. This box generally includes the following four parts: (1) Promoter: the protein coding region responsible for initiating gene transcription. (2) Codon-optimized coding sequence: information for guiding protein synthesis. (3) Terminator: the region that ends gene transcription. (4) Possible regulatory sequences: other regulatory elements used to regulate the intensity of gene expression.
[0101] GOI is the abbreviation of Gene of Interest.
[0102] The first aspect of the present application
[0103] A nucleic acid molecule, comprising: a nucleic acid fragment 1, a nucleic acid fragment 2, and an exogenous gene expression frame for expressing an exogenous fragment located between the nucleic acid fragment 1 and the nucleic acid fragment 2;
[0104] The complementary fragments of the nucleic acid fragment 1 and the nucleic acid fragment 2 are a tail-to-tail gene pair;
[0105] The nucleic acid fragment 1 and the nucleic acid fragment 2 are connected to a non-coding region, the 5' end of the non-coding region is taa and the 3' end is tta, and the exogenous fragment is inserted between taa and tta.
[0106] In some embodiments, the sequence of the non-coding region is taatta. In other embodiments, the length of the sequence of the non-coding region is 7 bp-200 bp, for example, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 185, 190, 195, 200 bp.
[0107] Inserting exogenous fragments into the nucleic acid molecule at the sites described in the embodiments of the present application does not affect the replication of the baculovirus and is stable in passage, and can achieve higher compatibility. For example, for the recombinant competent cells with the AAV expression frame inserted, it is only necessary to carry out the transformation and construction of the target gene with the shuttle plasmid of traditional Tn7 recombination, perform Tn7 recombination, and obtain the recombinant bacmid. After transfecting the host cells, the recombinant baculovirus packaged by the AAV can be obtained.
[0108] In some embodiments, the tail-to-tail gene pair is from a baculovirus. The baculovirus includes, but is not limited to, Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudocanthus pseudocytogenes multiple nucleocapsid nuclear polyhedrosis virus, Gypsy moth multiple nucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multiple nucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus, and Spodoptera litura nuclear polyhedrosis virus. The following examples of the present application take the tail-to-tail gene pair from Autographa californica nuclear polyhedrosis virus as an example to explain the technical solution of the present application, and it should be understood that the present application is not limited thereto.
[0109] In some embodiments, the exogenous fragment includes one or more of a selection marker gene and a target gene. The present application does not specifically limit the type of target gene, including but not limited to AAV packaging essential elements. The AAV packaging essential elements include one or more of a Cap gene, a Rep gene, and an ITR gene. The present application does not particularly limit the serotype of AAV packaged by the AAV packaging essential elements, such as the 13 different serotypes of AAV in primates (i.e., AAV1-AAV13) and related recombinant AVVs (e.g., rAAV2 / 1, rAAV2 / 2, rAAV2 / 3, rAAV2 / 3, rAAV2 / 4, rAAV2 / 5, rAAV2 / 6, rAAV2 / 7, rAAV2 / 8, rAAV2 / 9, rAAV2-retro, AAV-PHP.eB, AAV-PHP.S, AAV-PAN, AAV-LUNG, AAV-DJ, AAV-7m8, AAV-ShH10Y, AAV-Rh10, AAV-Anc80L65, AAV-SCH9). Optionally, the gene sequence of the Cap gene is a Cap8 sequence that is codon-optimized based on ribosome leak scanning, and further optionally, a sequence as shown in SEQ ID No.2. It is understood that the sequence of the Cap gene is not limited to the Cap8 sequence, and for example, it can also be a sequence of Cap9 contained in SEQ ID NO.54, a sequence of Cap5 contained in SEQ ID NO.55, or a sequence of Cap2 contained in SEQ ID NO.56. Optionally, the gene sequence of the Rep gene is a Rep2 sequence that is codon-optimized based on ribosome leak scanning, and further optionally, a sequence as shown in SEQ ID No.3. It is understood that the sequence of the Rep gene is not limited to the Rep2 sequence. Optionally, the ITR gene has a sequence as shown in SEQ ID No.4 (R-ITR) and SEQ ID No.5 (L-ITR).
[0110] In some embodiments, a GOI is inserted between the left ITR segment (L-ITR) and the right ITR segment (R-ITR) of the ITR gene. The present application does not specifically limit the type of GOI, and it can be any gene of interest to those skilled in the art, including but not limited to genes encoding some biologically active proteins (e.g., the EGFP gene shown in SEQ ID No. 6).
[0111] It is understood that in order to achieve the expression of the selection marker gene and / or target gene in the exogenous fragment, the exogenous fragment should contain the complete expression frame of the selection marker gene and / or target gene. In some embodiments, the exogenous gene expression frame includes a promoter that regulates the selection marker gene in the expression frame, including a baculovirus very early promoter, which is conducive to the rapid visualization of the infection titer detection of the recombinant baculovirus containing the nucleic acid molecule. In some embodiments, the exogenous gene expression frame includes a promoter that regulates the target gene in the expression frame, including a P10 promoter or a PH promoter, for example, the AAV packaging essential element is located downstream of the promoter and is regulated by the promoter.
[0112] The present application does not specifically limit the selection marker gene, including but not limited to luciferase gene, neomycin resistance gene, hygromycin phosphotransferase gene, dihydrofolate reductase gene, thymidine kinase gene, glutamine synthetase gene, asparagine synthetase gene, tryptophan synthetase gene, histidinol dehydrogenase gene, aminoglycoside phosphotransferase gene, tryptophan synthetase gene. The following examples of the present application take the luciferase gene as an example to explain the technical solution of the present application, and it should be understood that the present application is not limited thereto.
[0113] The present application does not specifically limit the target gene, including but not limited to: genes encoding one or more of antibodies, polypeptides, enzymes, hormones, growth factors and protein receptors.
[0114] It can be understood that, in order to achieve the purpose of homologous recombination, the nucleic acid molecule may contain a homology arm recognized by a recombinase, such as a RED recombinase, a Bxb1 integrase, a ΦC31 integrase, a Cre recombinase or a FLP recombinase, and the sequence of the homology arm may be, for example, a LoxP sequence, a LoxPL3 sequence, a LoxP 2L sequence, a LoxFas sequence, a Lox511 sequence, a Lox2272 sequence, a Lox2372 sequence, a Lox5171 sequence, a Loxm2 sequence, a Lox71 sequence, a Lox66 sequence, a FRT sequence, a Bxb1 attP sequence, a Bxb1 attB sequence, an attP sequence, an attB, an attL sequence and an attR sequence.
[0115] In some embodiments, the tail-to-tail gene pair comprises any one of the following gene pairs:
[0116] Gene pair 1 is the lef4 gene and the orf91 gene, and the corresponding insertion site is denoted as the OB1 site;
[0117] Gene pair 2 is the p15 gene and the cg30 gene, and the corresponding insertion site is recorded as the OB2 site; and,
[0118] Gene pair 3 is the env-prot gene and the pkip gene, and the corresponding insertion site is denoted as the OB3 site.
[0119] In some embodiments, the sequence of the non-coding region comprises the sequence shown in SEQ ID NO.1.
[0120] Taking the AcMNPV genome as an example: the lef4 gene and the orf91 gene are a tail-to-tail gene pair, and there is a reverse overlapping termination codon ttaa between the two. After ttaa is changed to taatta to form a reversely connected termination codon, the exogenous fragment is inserted at the position between taa and tta (i.e., between 77990bp and 77991bp, corresponding to the OB1 site); the p15 gene and the cg30 gene are a tail-to-tail gene pair, and there is a non-coding region with a sequence of taatta between the two, which is a reversely connected termination codon between the two. The exogenous fragment can be directly inserted at the position between taa and tta (i.e., between 74736bp and 74737bp, corresponding to the OB2 site); there is a non-coding region with a length of 48bp as shown in SEQ ID NO.1 between the env-prot gene and the pkip gene. The exogenous fragment can be inserted at any site of the non-coding region with a length of 48bp, or the non-coding region with a length of 48bp can be knocked out and the exogenous fragment can be directly inserted between the env-prot gene and the pkip gene.
[0121] In some embodiments, the sequence of the nucleic acid molecule is as shown at 2779bp to 4912bp in SEQ ID NO.44, at 2779bp to 11984bp in SEQ ID NO.46, at 2779bp to 8988bp in SEQ ID NO.47, at 2903bp to 8875bp in SEQ ID NO.48, at 2861bp to 8881bp in SEQ ID NO.49, at 749bp to 4910bp in SEQ ID NO.50, at 749bp to 4776bp in SEQ ID NO.52, or at 2903bp to 6930bp in SEQ ID NO.53.
[0122] The second aspect of the embodiment of the present application
[0123] A recombinant plasmid comprises the nucleic acid molecule.
[0124] In some embodiments, the recombinant plasmid comprises a shuttle plasmid. Further, the recombinant plasmid is shown in SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.
[0125] The third aspect of the embodiment of the present application
[0126] A recombinant baculovirus, the genome of which includes the nucleic acid molecule.
[0127] The present application does not specifically limit the recombinant baculovirus, including but not limited to Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudococcus pyogenes multinucleocapsid nuclear polyhedrosis virus, Gypsy moth multinucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multinucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus or Spodoptera litura nuclear polyhedrosis virus. The following examples of the present application are explained by taking Autographa californica nuclear polyhedrosis virus as an example to explain the technical scheme of the present application, and it should be understood that the present application is not limited thereto. Recombinant baculovirus (BEV) has the following advantages as an exogenous gene expression vector: the baculovirus genome is relatively small and easy to operate, the exogenous gene fragments that can be accommodated are large, and the safety is high. Currently, the most widely used recombinant baculovirus (BEV) is based on the genome of Autographa californica nuclear polyhedrosis virus (AcMNPV). The AcMNPV genome is a double-stranded circular DNA with a total length of 133,894 bp. The sequence and map refer to GenBank: NC_001623.
[0128] In some embodiments, the genome of the recombinant baculovirus has one or more deletions of the Chia gene and the Cath gene. The Chia and V-Cath genes are non-essential genes for baculovirus replication. Removing the chiA and v-cath encoding genes in the baculovirus genome can improve the secretion efficiency of recombinant proteins and the stability of intracellular proteins, and can make any protein expressed at an excessive level, including secretory proteins, cell membrane proteins, or proteins that are particularly easy to degrade.
[0129] In some embodiments, other loci of the genome of the recombinant baculovirus are inserted with exogenous fragments as defined above.
[0130] The recombinant baculovirus provided by the present application has the exogenous fragment inserted into any one of the OB1 site, OB2 site and OB3 site.
[0131] In some embodiments, in the recombinant baculovirus, the exogenous fragment is inserted into the OB1 site. The exogenous fragment may include the selection marker gene and the target gene at the same time, and the target gene may include the AAV packaging essential elements, and the AAV packaging essential elements include the Cap gene, Rep gene and ITR gene, such as the technical solution described in Example 2. The exogenous fragment may only include the target gene, and the target gene may include the AAV packaging essential elements, and the AAV packaging essential elements include the Cap gene, Rep gene and ITR gene, such as the technical solution described in Example 4.
[0132] In some embodiments, in the recombinant baculovirus, the OB2 site is inserted into the exogenous fragment, and the exogenous fragment may only include the target gene, and the target gene may include AAV packaging essential elements, and the AAV packaging essential elements include the Cap gene, Rep gene and ITR gene, such as the technical solution described in Example 6.
[0133] In some embodiments, in the recombinant baculovirus, the exogenous fragment is inserted into the OB3 site. The exogenous fragment may only include the selection marker gene, such as the technical solution described in Example 9.
[0134] In the recombinant baculovirus provided by the present application, some of the exogenous fragments are inserted into any one of the OB1 site, the OB2 site and the OB3 site, and some of the fragments are inserted into other gene loci; optionally, the other gene loci include the polh gene (taking the parent bacmid bMON14272 as an example, the attTn7 transposition site of the polh gene can be inserted, denoted as the Tn7 site).
[0135] In some embodiments, the exogenous fragments include a selection marker gene and a target gene, the target gene includes an AAV packaging essential element, the selection marker gene is inserted into the OB1 site, and the target gene is inserted into the Tn7 site. Optionally, a GOI (e.g., EGFP gene) is inserted between the left ITR segment and the right ITR segment of the ITR gene in the AAV packaging essential element, such as the technical solution described in Example 1.
[0136] In some embodiments, some of the elements essential for AAV packaging are inserted into any one of the OB1 site, the OB2 site, and the OB3 site, and the remaining elements are inserted into other loci. Optionally, a GOI (e.g., an EGFP gene) is inserted between the left ITR segment and the right ITR segment of the ITR gene in the AAV essential elements for packaging. In one embodiment, the ITR gene is inserted into the other loci, and the Cap gene and the Rep gene are inserted into the OB1 site, such as the solution described in Example 3. In another embodiment, the Cap gene and the Rep gene are inserted into the OB2 site, and the ITR gene is inserted into the other loci, such as the technical solution described in Example 7. In yet another embodiment, the Cap gene and the Rep gene are inserted into the OB3 site, and the ITR gene is inserted into the other loci, such as the technical solution described in Example 8.
[0137] The recombinant baculovirus provided by the present application has exogenous fragments inserted into multiple sites (e.g., 2 or 3) among the OB1 site, the OB2 site, and the OB3 site. Among the essential elements for AAV packaging, the Cap gene, the Rep gene, and the ITR gene are respectively inserted into 3 sites (with no corresponding relationship to the sites), or two of the elements are inserted into one of the three sites, and the remaining element is inserted into one of the remaining sites. For example, the technical solution described in Example 10.
[0138] In some embodiments, the selection marker gene is inserted into any one of the OB1 site, the OB2 site and the OB3 site. Inserting the selection marker gene into the OB1, OB2 or OB3 site can be applied to the rapid visual detection of the infection titer of BEV.
[0139] The fourth aspect of the embodiment of the present application
[0140] A method for constructing the recombinant baculovirus, the method comprising the following steps:
[0141] causing homologous recombination between the donor plasmid and the baculovirus genome, thereby constructing a recombinant baculovirus;
[0142] The donor plasmid comprises the nucleic acid molecule.
[0143] In some embodiments of the present application, the recombinase used in homologous recombination includes RED recombinase, Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.
[0144] In some embodiments of the present application, the donor plasmid comprises a shuttle plasmid.
[0145] In some embodiments of the present application, the donor plasmid is shown as SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.
[0146] A fifth aspect of the present application
[0147] An adeno-associated virus packaging vector system comprises essential elements for AAV packaging, wherein the essential elements for AAV packaging include one or more of Cap gene, Rep gene and ITR gene; the essential elements for AAV packaging are located in the same or different nucleic acid molecules.
[0148] In some embodiments, a GOI is inserted between the left ITR segment and the right ITR segment of the ITR gene. The present application does not specifically limit the type of GOI, and it can be any gene of interest to those skilled in the art, including but not limited to genes encoding some biologically active proteins (e.g., the EGFP gene shown in SEQ ID No. 6).
[0149] The sixth aspect of the embodiment of the present application
[0150] A method for producing an expression product of an exogenous fragment, the production method comprising the following steps:
[0151] The host cells are infected with the recombinant baculovirus and then cultured, and the expression product of the exogenous fragment is separated from the obtained culture product.
[0152] In the application examples, the host cell includes an insect cell line. The insect cell line includes, but is not limited to, a lepidopteran insect cell line. The lepidopteran insect cell line includes, but is not limited to, a fall armyworm cell line, a silkworm cell line, or a cabbage looper cell line. The lepidopteran insect cell line includes, but is not limited to, an ovarian tissue cell line or a fat body cell line. The most widely used insect cell lines are the cabbage looper fall armyworm ovarian cell line (Sf21), Sf9 cells cloned from Sf21 cells, and H5 (high five) cell lines.
[0153] In some embodiments, the production method further comprises the step of detecting the titer of the obtained recombinant baculovirus.
[0154] In some embodiments, the titer of the obtained recombinant baculovirus is detected by a standard curve method, comprising the following steps:
[0155] Providing a standard curve, wherein the standard curve reflects the linear relationship between the luciferase activity value and the virus titer value; and,
[0156] Detecting the activity value of luciferase expressed by the luciferin gene in the recombinant baculovirus to be tested, substituting it into the standard curve, and calculating the virus titer value of the recombinant baculovirus to be tested;
[0157] The activity value of the luciferase = the luminescence intensity value generated by the luciferase expressed by the recombinant baculovirus - the luminescence intensity value of the virus-free control substance.
[0158] The seventh aspect of the embodiment of the present application
[0159] One or more embodiments of the present application also provide a method for producing a recombinant adeno-associated virus or a GOI expression product, wherein the production method uses the adeno-associated virus packaging vector system.
[0160] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.
[0161] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0162] Combination Figure 1 In the present application, the genome sequence of baculovirus AcMNPV (Autographa californica nuclear polyhedrosis virus) was analyzed, and multiple baculovirus conserved gene loci were selected for testing, and finally three loci were preferably designed: the OB1 locus is the reverse overlapping stop codon ttaa located at 77987-77990 bp between the C-termini of Ac-lef-4 and Ac-orf-91, and after ttaa is changed to taatta to form a reverse-connected stop codon, the reverse-connected stop codon connection point is located at 77990 bp; the OB2 locus is the reverse-connected stop codon connection point located at 74736 bp between the C-termini of the conserved gene locus Ac-p15 and Ac-cg30; the OB3 locus is the 48 bp non-coding region located at 20586-20633 bp between the C-termini of the conserved gene locus Ac-env-prot and Ac-pkip (SEQ ID NO.1).
[0163] Example 1. Obtaining a recombinant baculovirus expressing the reporter gene Luciferase and Tn7 recombinant 8KC-EGFP at the OB1 insertion site, R0329 {rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}
[0164] 1 Construction of the Gluc expression cassette baculovirus vector GLuc(OB1)-ΔCC-DH10Bac
[0165] 1.1 Preparation of pKD46 / ΔCC-DH10Bac competent cells
[0166] (1) Preparation of pKD46 / DH10Bac competent cells
[0167] The pKD46 plasmid is a temperature-sensitive low-copy plasmid. At 30°C, adding arabinose to the culture medium of cells transfected with the pKD46 plasmid can induce the expression of three proteins, Exo, Beta and Gam (i.e., Red recombinase), and can efficiently and specifically recombine the exogenous genes carrying homology arms with the bacmid genome in bacteria (see Doublet et al., 2008, J Microbiol Methods., 75(2):359-61).
[0168] In the present application, pKD46 was transformed into DH10Bac competent cells, cultured at 30°C throughout the process, and the competent cells were shaken after screening and identification. 100 mM (final concentration) L-arabinose was added at OD600 of 0.2 and induced for 2 hours to prepare pKD46 / DH10Bac competent cells.
[0169] Primers for identifying the Bet gene of pKD46: the sequence of Bet-F is 5'-atgagtactgcactcgcaa-3' (SEQ ID NO.20), and the sequence of Bet-R is 5'-tgctctgcggctttctgtt-3' (SEQ ID NO.21); amplified fragment size: 768 bp; if a 768 bp amplified fragment is detected, it is judged as a positive bacterium;
[0170] Primers for identifying the araC gene of pKD46: the sequence of araC-F is 5'-ttatgacaacttgacggctaca-3' (SEQ ID NO.22), and the sequence of araC-R is 5'-atggctgaagcgcaaaatga-3' (SEQ ID NO.23); amplified fragment size: 879 bp; if an 879 bp amplified fragment is detected, it is judged as a positive bacterium.
[0171] The electrophoresis diagram of PCR identification of pKD46 / DH10Bac competent cells is shown in Figure 2. Figure 2 Middle: Marker is 2000bp, lanes 1, 2, 3, and 4 are electrophoresis bands of the PCR products of the Bet gene of pKD46 with identification primers of No. 1 to 4, the target band size is 768bp, and the detected bacteria are positive bacteria; lanes 5, 6, 7, and 8 are electrophoresis bands of the PCR products of the araC gene of pKD46 with identification primers of No. 1 to 4, the target band size is 879bp, and the detected bacteria are positive bacteria. Among them, the number 3 of the bacterial selection is the target positive strain of pKD46 / DH10Bac that meets the identification requirements.
[0172] (2) Preparation of ΔCC-DH10Bac competent cells
[0173] The present application knocks out the Chia and V-Cath genes of the baculovirus (the Chia and V-Cath genes are non-essential genes for baculovirus replication. Removing the chiA and v-cath encoding genes in the baculovirus genome can improve the secretion efficiency of recombinant proteins and the stability of intracellular proteins, and can make any protein over-expressed, including secretory proteins, cell membrane proteins or proteins that are particularly easy to degrade):
[0174] The DH10Bac competent cells were shaken to extract the AcMNPV genomic bacmid bMON14272. Using the AcMNPV genomic bacmid bMON14272 as a template, primers HAL(lef7)-F (SEQ ID NO.24): 5'-gggtgtacaggtaacggccaatt-3' and HAL(lef7)-R (SEQ ID NO.25): 5'-TCCCCCCGGGaagcaatatattgagtatcaTTTTAG-3' were designed to amplify the fragment HAL(lef7) (420 bp) (sequence shown in SEQ ID NO.7). Using the AcMNPV genomic bacmid bMON14272 as a template, primers HAR(GP64)-F (SEQ ID NO.26): 5'-ACATGcatgctctcaacacactcgctatttgga-3' and HAR(GP64)-R (SEQ ID NO.27): 5'-ACATGcatgctctcaacacactcgctatttgga-3' were designed to amplify the fragment HAL(lef7) (420 bp) (sequence shown in SEQ ID NO.7). NO.27): 5'-AGCTTTGTTTAAACtggagaacaccaagtttg-3', amplified fragment HAR (GP64) (430 bp) (sequence as shown in SEQ ID NO.8);
[0175] In order to facilitate the screening of recombinants, a chloramphenicol (CmR) resistance gene with Frt fragments on both sides was introduced, and primers Nhe IF (SEQ ID NO.28): 5'-ctaGCTAGCgtgtaggctggag-3' and HindIII-R (SEQ ID NO.29): 5'-cccAAGCTTatgggaattagccatg-3' were designed to amplify fragment P1-FRT-CmR-P2 (1053 bp) from the pKD3 plasmid (the sequence is shown in SEQ ID NO.9).
[0176] HAL(lef7) (420 bp), HAR(GP64) (430 bp) and P1-FRT-CmR-P2 (1053 bp) were cloned on the vector plasmid pQB1064 by molecular cloning recombination with restriction enzyme cutting sites to obtain pQB1064-HAL(lef7)-P1-FRT-CmR-P2-HAR(GP64) plasmid. After linearization of the pQB1064-HAL(lef7)-P1-FRT-CmR-P2-HAR(GP64) plasmid, the DNA fragment HAL(lef7)-P1-FRT-CmR-P2-HAR(GP64) was obtained by gel recovery. 4), transforming the DNA fragment into pKD46 / DH10Bac (the selection plate number 3 in step (1)) competent cells, knocking out the Chia and V-Cath genes of the baculovirus, selecting the monoclonal bacterial solution of pKD46 / CmR-ΔCC-DH10Bac by resistance (chloramphenicol resistance) plate screening, culturing at 42°C to eliminate the pKD46 plasmid, selecting on resistance plates to prepare CmR-ΔCC-DH10Bac competent cells, transforming the pCP20 plasmid into the CmR-ΔCC-DH10Bac competent cells, culturing at 42°C to eliminate the pCP20 plasmid, and selecting and identifying to prepare ΔCC-DH10Bac competent cells.
[0177] ΔCC-DH10Bac identification primers:
[0178] Identification primers for the Bet gene of pKD46: Bet-F (SEQ ID NO.20): 5'-atgagtactgcactcgcaa-3' and Bet-R (SEQ ID NO.21): 5'-tgctctgcggctttctgtt-3'; amplified fragment size: 768 bp; if an amplified fragment of 768 bp is detected, it is a negative strain;
[0179] Primers for successful identification of homologous arm recombination: pCAT-HAL (lef7) -F (SEQ ID NO.30): 5'-cgatcaactttctcgccaac-3' and pCAT-HAR (gp64) -R (SEQ ID NO.31): 5'-gactcgtcgcaatgcata-3'; amplified fragment size: 1347 bp; if an amplified fragment of 1347 bp is detected, it is a positive strain; primers FLP-F (SEQ ID NO.32) of pCP20 plasmid: 5'-CCCTTGCGCTAAAGAAGT-3' and FLP-R (SEQ ID NO.33): 5'-GAGAGCCACATTCATGAG-3'; amplified fragment size: 551 bp; if an amplified fragment of 551 bp is detected, it is a negative strain;
[0180] Primers for identifying CmR sequence: pCAT-Chl-F (SEQ ID NO.34): 5'--tgatcggcacgtaagaggtt-3' and pCAT-Chl-R (SEQ ID NO.35): 5'--actggtgaaactcaccca-3'; amplified fragment size: 568 bp; if the amplified fragment is detected, it is a negative strain.
[0181] The electrophoresis diagram of PCR identification of ΔCC-DH10Bac is shown in Figure 3 . Figure 3 In Figure A, the marker is 2000bp. Lanes 1, 2, 3, 4, and 5 are electrophoretic bands of the PCR products of the identification primers for the Bet protein of pKD46 of the strain selection number 1 to 5. The target band size is 768bp, indicating negative bacteria. Lanes 6, 7, 8, 9, and 10 are electrophoretic bands of the PCR products of the identification primers pCAT-HAL (lef7) -F and pCAT-HAL (gp64) -R of the homologous arm recombination of the strain selection number 1 to 5. The target band size is 1347bp, indicating positive bacteria. Lanes 11, 12, 13, 14, and 15 are electrophoretic bands of the PCR products of the identification primers for the pCP20 plasmid of the strain selection number 1 to 5. The target band size is 551bp, indicating negative bacteria. Figure 3 In the middle B figure, the marker is 2000bp, and lanes 1, 2, 3, 4, and 5 are electrophoresis bands of the PCR products of the identification primers of the CmR fragments of the strains numbered 1 to 5. The target band size is 568bp, which is negative bacteria. Among them, the strains numbered 3 and 4 are the target positive strains of ΔCC-DH10Bac that meet the identification requirements.
[0182] (3) Preparation of pKD46 / ΔCC-DH10Bac competent cells
[0183] The pKD46 plasmid was transformed into ΔCC-DH10Bac competent cells, and the whole process was cultured at 30℃. After screening and identification, the competent cells were shaken. After adding 100mM L-arabinose for induction for 2 hours at OD600 of 0.2, the L-arabinose-induced electroporation competent cells of pKD46 / ΔCC-DH10Bac were prepared. The identification primers of pKD46 / ΔCC-DH10Bac are:
[0184] Bet gene Bet-F (SEQ ID NO.20) of pKD46: 5'-atgagtactgcactcgcaa-3' and Bet-R (SEQ ID NO.21): 5'-tgctctgcggctttctgtt-3'; amplified fragment size: 768 bp; if the amplified fragment is detected, it is judged as a positive bacterium;
[0185] The primers for successful identification of homologous arm recombination were pCAT-HAL(lef7)-F (SEQ ID NO.30): 5'-cgatcaactttctcgccaac-3' and pCAT-HAR(gp64)-R (SEQ ID NO.31): 5'-gactcgtcgcaatgcata-3'; the size of the amplified fragment was 1347 bp; if the amplified fragment was detected, it was judged as a positive bacterium.
[0186] The electrophoresis diagram of PCR identification of pKD46 / ΔCC-DH10Bac is shown in Figure 4 . Figure 4 In Figure A, the markers of the lanes are 2000 bp and 10000 bp respectively. Lanes 1, 2, 3, and 4 are the electrophoresis bands of the PCR products of the Bet gene of pKD46 with identification primers of number 1 to 4 in the bacterial picking shake. The target band size is 768 bp, indicating positive bacteria. Figure 4 In Figure B, the marker is 2000bp, and lanes 1, 2, 3, and 4 are the electrophoresis bands of the PCR products of the homologous arm recombination of the strains No. 1 to 4, which were successfully identified using the primers pCAT-HAL(lef7)-F and pCAT-HAL(gp64)-R. The target band size is 1347bp, indicating positive bacteria; among them, the strains No. 1 and 2 are the target positive strains of pKD46 / ΔCC-DH10Bac that meet the identification requirements.
[0187] 1.2 Preparation of CmR-GLuc(OB1)-ΔCC-DH10Bac competent cells
[0188] Similarly, using AcMNPV genomic bacmid bMON14272 as a template, primers HAL(lef4)-F (SEQ ID NO.36): 5'-ccaATGCATtcatacgctatagatccg-3' and HAL(lef4)-R (SEQ ID NO.37): 5'-tccCCCGGGttaatttggcacgattcg-3' were designed to amplify the fragment HAL(lef4) (420 bp) (sequence shown in SEQ ID NO.10); using AcMNPV genomic bacmid bMON14272 as a template, primers HAR(ORF91)-F (SEQ ID NO.38): 5'-acatGCATGCttaaagcacgttaagcg-3' and HAR(ORF91)-R (SEQ ID NO.39): 5'-acatGCATGCttaaagcacgttaagcg-3' were designed to amplify the fragment HAL(lef4) (420 bp) (sequence shown in SEQ ID NO.10). NO.39): 5'-agctttGTTTAAACtccaccttctcctat-3', amplified fragment HAR (ORF91) (344 bp) (sequence as shown in SEQ ID NO.11);
[0189] In this embodiment, the baculovirus early to late ETL promoter is used to regulate the Luciferase reporter gene, and the expression frame of the Luciferase reporter gene with the SV40PA element is ETL-Luciferase-SV40pA (sequence as shown in SEQ ID NO.12). Since ETL belongs to the early to late promoter, the expression of Luciferase can be started at an earlier time after BEV infects the host cell. The sequence pETL-GLuc-Dura-SV40pA was commissioned to be synthesized by a biotechnology company.
[0190] Using the molecular cloning recombination method of restriction enzyme cutting sites, HAL (lef4) (420bp), HAR (ORF91) (344bp), P1-FRT-CmR-P2 (1053bp) and the synthetic fragment pETL-GLuc-Dura-SV40pA were cloned on the vector plasmid pQB1064 to obtain pQB1064-HAL (lef4) -P1-FRT-CmR-P2-pETL-GLuc-Dura-SV40pA-HAR (ORF91) plasmid (SEQ ID NO.44, the vector sequence of SEQ ID NO.44 will clarify the actual sequence and position of GLuc (OB1) at the OB1 site). After linearization of the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-HAR(ORF91) plasmid, the DNA fragment HAL(lef4)-P1-FRT-CmR-P2-pETL-GLuc-Dura-SV40Pa-HAR(ORF91) was obtained by gel recovery. The DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac (pKD46 / ΔCC-DH10Bac with the strain number 1), and the monoclonal bacterial solution of pKD46 / CmR-GLuc(OB1)-ΔCC-DH10Bac was obtained by screening and identification. After culturing at 42°C to eliminate the pKD46 plasmid, the competent cell of CmR-GLuc(OB1)-ΔCC-DH10Bac was prepared by resistance plate screening.
[0191] During the experiment, it was found that after the pCP20 plasmid was transformed into a competent state with a chloramphenicol expression frame after two knockouts, all the target fragments of the knockout insertion were identified to be lost. The reason is that after the knockout using RED recombination, an FRT target site will be left on one side. After two knockouts, two FRT target sites will be left, which will form unidirectional complementation and form a large-fragment knockout, thus retaining the chloramphenicol resistance expression frame left by the knockout.
[0192] 2 Obtaining recombinant baculovirus R0329 {rBEV-GLuc(OB1)-8KC-EGFP(Tn7)} through Tn7 recombination
[0193] A cloning vector for co-expression of the packaging elements of adeno-associated virus AAV8 was constructed using the AAV8-EGFP packaging element expression cassette (sequence as shown in SEQ ID NO.13) composed of Cap8 (sequence as shown in SEQ ID NO.2), Rep2 (sequence as shown in SEQ ID NO.3) and ITR-EGFP (sequence as shown in SEQ ID NO.6) disclosed in the present application.
[0194] pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45, the vector sequence of SEQ ID NO.45 will clarify the actual sequence and position of 8KC-EGFP (Tn7) at the Tn7 site), and then use pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR to transform the CmR-GLuc(OB1)-ΔCC-DH10Bac competent cells prepared in step 1.2, screen the recombinant clones by blue-white screening, extract the recombinant BacmidDNA by shaking, and transfect the BacmidDNA into the host cell line for culture. After 4 days of culture, the recombinant baculovirus is obtained.
[0195] R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P0 was transferred into suspension Sf9 cells for 3 days. The recombinant baculovirus that replicated and proliferated further infected the Sf9 cells to obtain a higher titer of seed virus. The partially packaged cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was packaged and stored, which was the harvested recombinant baculovirus R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1. The remaining packaged cell suspension was used to purify the recombinant adeno-associated virus R0329-AAV8-EGFP after virus collection. The virus was infected as follows Fig.17 Lane 1.
[0196] The genome diagram of R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)} is shown in Figure 5 .
[0197] Example 2. Obtaining a recombinant baculovirus containing an AAV8-EGFP packaging element expression cassette at the OB1 insertion site, R0330 {rBEV-8KC-EGFP (OB1)}
[0198] 1. Preparation of CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac competent cells
[0199] A cloning vector for co-expression of the packaging elements of adeno-associated virus AAV8 constructed using Example 1
[0200] pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45) was digested and gel-recovered to obtain a linearized DNA fragment of the AAV8-EGFP packaging element expression cassette (sequence as shown in SEQ ID NO.13). HAL (lef4) (420 bp), HAR (ORF91) (344 bp), P1-FRT-CmR-P2 (1053 bp) and the AAV8-EGFP packaging element expression cassette (sequence as shown in SEQ ID NO.13) were recombined by molecular cloning and recombination using restriction enzyme cutting sites. The linearized DNA fragment was cloned into the vector plasmid pQB1064 (SEQ ID NO. 13) to obtain the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-8KC-EGFP-HAR(ORF91) plasmid (SEQ ID NO. 46, the vector sequence of SEQ ID NO. 46 will clarify the actual sequence and position of 8KC-EGFP (OB1) at the OB1 site). After linearization of the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-8KC-EGFP-HAR(ORF91) plasmid, the DNA fragment HAL(lef4)-P1-FRT-CmR-P2-8KC-EGFP-HAR(ORF91) was recovered by gel recovery, and the DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac. The monoclonal bacterial solution of pKD46 / CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac was screened and identified. After culturing at 42°C to eliminate the pKD46 plasmid, the CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac competent cell was prepared by resistance plate screening.
[0201] 2. Extract the bacmid and transfect the host cells to obtain the recombinant baculovirus R0330 {rBEV-8KC-EGFP (OB1)}
[0202] CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac competent cells were shaken, recombinant Bacmid DNA was extracted, and the Bacmid DNA was transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0330{rBEV-8KC-EGFP(OB1)}#P0 was obtained, which was transferred into the suspension Sf9 cells for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities further infected the Sf9 cells to obtain a higher titer of seed virus. The partially packaged cell suspension was centrifuged at 3000rpm for 5min, and the supernatant was packaged and stored, which was the harvested recombinant baculovirus R0330{rBEV-8KC-EGFP(OB1)}#P1. The remaining packaged cell suspension was used to purify the recombinant adeno-associated virus R0330-AAV8-EGFP after the virus was collected. The genome schematic diagram of R0330{rBEV-8KC-EGFP(OB1)} is shown below. Figure 6 The fluorescence photos of cells of R0330{rBEV-8KC-EGFP(OB1)}#P1 were expanded to P7 at a fixed inoculation starting density and inoculation MOI. Fig.15 ; As shown in the figure, the expression of the target gene EGFP fluorescence inserted into the OB1 site remained stable in the P7 generation.
[0203] Example 3. Obtaining recombinant baculoviruses with packaging element expression cassettes of AAV9-EGFP, AAV5-EGFP and AAV2-EGFP respectively loaded at the OB1 insertion site, R0338 {rBEV-9KC-EGFP (OB1)}, R0339 {rBEV-5KC-EGFP (OB1)} and R0340 {rBEV-2KC-EGFP (OB1)}
[0204] 1 Preparation of CmR-9KC-EGFP(OB1)-ΔCC-DH10Bac, CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac and CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac competent cells
[0205] The synthetic sequences p10-Cap9-PA (SEQ ID NO.54), p10-Cap5-PA (SEQ ID NO.55) and p10-Cap2-PA (SEQ ID NO.56) were sent respectively.
[0206] The pQB1064-HAL(lef4)-P1-FRT-CmR-P2-8KC-EGFP-HAR(ORF91) plasmid (SEQ ID NO.46) was constructed using Example 1. Through the restriction sites at both ends of each sequence of p10-Cap9-PA (SEQ ID NO.54), p10-Cap5-PA (SEQ ID NO.55) and p10-Cap2-PA (SEQ ID NO.56), the Cap8 sequence marked in the SEQ ID NO.46 sequence was replaced with Cap9, Cap5 and Cap2 to obtain the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-9KC-EGFP-HAR(ORF91) plasmid, pQB1064-HAL(lef4)-P1-FRT-CmR-P2-5KC-EGFP-HAR(ORF91) plasmid and pQB1064-HAL(lef4)-P1-FRT-CmR-P2-2KC-EGFP-HAR(ORF91) plasmid. After linearization of the above plasmids, the DNA fragments HAL(lef4)-P1-FRT-CmR-P2-9KC-EGFP-HAR(ORF91), HAL(lef4)-P1-FRT-CmR-P2-5KC-EGFP-HAR(ORF91) and HAL(lef4)-P1-FRT-CmR-P2-2KC-EGFP-HAR(ORF91) were obtained by gel recovery. The above DNA fragments were transformed into the L-arabinose-induced electroporation competent cells of pKD46 / ΔCC-DH10Bac, and pKD46 / CmR-9KC-EGFP-HAR(ORF91) was obtained by screening and identification. The monoclonal bacterial solutions of FP(OB1)-ΔCC-DH10Bac, pKD46 / CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac and pKD46 / CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac were cultured at 42°C to eliminate the pKD46 plasmid, and then screened on resistance plates to prepare CmR-9KC-EGFP(OB1)-ΔCC-DH10Bac, CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac and CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac competent cells.
[0207] 2 Recombinant baculoviruses R0338{rBEV-9KC-EGFP(OB1)}, R0339{rBEV-5KC-EGFP(OB1)} and R0340{rBEV-2KC-EGFP(OB1)} were obtained by extracting the bacmid and transfecting the host cells.
[0208] CmR-9KC-EGFP(OB1)-ΔCC-DH10Bac, CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac and CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac competent cells were shaken, and recombinant bacmid DNA was extracted respectively. The bacmid DNA was transfected into the host cell line for culture. After 4 days of culture, recombinant baculovirus R0338{rBEV-9KC-EGFP(OB1)}#P0, R0339{rBEV-5KC-EGFP(OB1)}#P0 and R0340{rBEV-2KC-EGFP(OB1)}#P0 were obtained, and transferred into suspension Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected, resulting in Sf9 cells obtaining higher titer of seed virus. The packaged part was centrifuged at 3000rpm for 5min. The cell suspension was divided into aliquots and stored as the harvested recombinant baculoviruses R0338{rBEV-9KC-EGFP(OB1)}#P1, R0339{rBEV-5KC-EGFP(OB1)}#P1 and R0340{rBEV-2KC-EGFP(OB1)}#P1. The remaining packaged cell suspensions were used to purify the recombinant adeno-associated viruses R0338-AAV9-EGFP, R0339-AAV5-EGFP and R0340-AAV2-EGFP. The electrophoresis images were as shown in Fig.18 The genome diagrams of R0338, R0339 and R0340 are the same as those of R0330. Figure 6 .
[0209] Example 4. Obtaining a recombinant baculovirus containing the AAV8 packaging element expression cassette and Tn7 recombinant ITR-EGFP at the OB1 insertion site, R0331 {rBEV-8KC (OB1) -EGFP (Tn7)}
[0210] 1. Preparation of CmR-8KC(OB1)-ΔCC-DH10Bac competent cells
[0211] A cloning vector for co-expression of the packaging elements of adeno-associated virus AAV8 constructed using Example 1
[0212] pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45) was digested and gel-recovered to obtain a linearized DNA fragment of the AAV8 packaging element expression cassette (sequence as shown in SEQ ID NO.14). The linearized DNA fragments of HAL (lef4) (420 bp), HAR (ORF91) (344 bp), P1-FRT-CmR-P2 (1053 bp) and the AAV8 packaging element expression cassette (sequence as shown in SEQ ID NO.14) were cloned on the vector plasmid pQB1064 to obtain the pQB1064-HAL (lef4) -P1-FRT-CmR-P2-8KC-HAR (ORF91) plasmid (SEQ ID NO.47, SEQ ID NO. The vector sequence of ID NO.47 will clarify the actual sequence and position of OB1 site 8KC (OB1). After linearizing the pQB1064-HAL (lef4) -P1-FRT-CmR-P2-8KC-HAR (ORF91) plasmid, the DNA fragment HAL (lef4) -P1-FRT-CmR-P2-8KC-HAR (ORF91) was recovered by gel recovery, and the DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac, and the monoclonal bacterial solution of pKD46 / CmR-8KC (OB1) -ΔCC-DH10Bac was obtained by screening and identification. After culturing at 42°C to eliminate the pKD46 plasmid, the CmR-8KC (OB1) -ΔCC-DH10Bac competent cell was prepared by resistance plate screening.
[0213] 2 Obtaining recombinant baculovirus R0331 {rBEV-8KC (OB1)-EGFP (Tn7)} through Tn7 recombination
[0214] A cloning vector for co-expression of the packaging elements of adeno-associated virus AAV8 constructed using Example 1
[0215] pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45) was digested and gel-recovered to obtain a linearized DNA fragment of the packaging element expression cassette of ITR-EGFP (the sequence is shown in SEQ ID NO.6), and a cloning vector pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR (the sequence is shown in SEQ ID NO.15, and the vector sequence of SEQ ID NO.15 will clarify the actual sequence and position of EGFP (Tn7) at the Tn7 site) was constructed, and then the pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR plasmid was used to transform CmR-8KC(OB1)-ΔCC-DH10Bac competent cells, and the recombinant clones were screened by blue-white screening, and the recombinant Bacmid DNA was extracted by shaking, and the Bacmid The DNA was transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0331{rBEV-8KC(OB1)-EGFP(Tn7)}#P0 was obtained, which was transferred into the suspended Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities further infected the Sf9 cells, resulting in a higher titer of seed virus. The partially packaged cell suspension was centrifuged at 3000rm5min, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0331{rBEV-8KC(OB1)-EGFP(Tn7)}#P1. The remaining packaged cell suspension was used to purify the recombinant adeno-associated virus R0331-AAV8-EGFP after the virus was collected.
[0216] The genome diagram of R0331{rBEV-8KC(OB1)-EGFP(Tn7)} is shown in Figure 7 .
[0217] Example 5. Obtaining a recombinant baculovirus carrying an AAV8 packaging element expression cassette at the OB1 insertion site, R0332 {rBEV-8KC (OB1)}
[0218] Example 4 was used to construct CmR-8KC(OB1)-ΔCC-DH10Bac competent cells. The CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were shaken to extract recombinant Bacmid DNA. The Bacmid DNA was transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0332{rBEV-8KC(OB1)}#P0 was obtained. The recombinant baculovirus was transferred into the suspension Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected to obtain a higher titer of seed virus in the Sf9 cells. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored to obtain the recombinant baculovirus R0332{rBEV-8KC(OB1)}#P1. The genome schematic diagram of R0332{rBEV-8KC(OB1)} is shown in FIG. Figure 8 .
[0219] Example 6. Obtaining a recombinant baculovirus carrying an AAV8 packaging element expression cassette at the OB1 insertion site, R0004 {rBEV-EGFP (Tn7)}
[0220] The cloning vector pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR (sequence shown in SEQ ID NO.15) obtained in Example 4 was used to transform the ΔCC-DH10Ba competent cells prepared in Example 1 with the pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR plasmid. The recombinant clones were screened by blue-white screening, and the recombinant Bacmid DNA was extracted by shaking. The Bacmid DNA was transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0004{rBEV-EGFP(Tn7)}#P0 was obtained, which was transferred to suspension Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected to obtain a higher titer of seed virus in the Sf9 cells. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0004{rBEV-EGFP(Tn7)}#P1. The genome diagram of R0004{rBEV-EGFP(Tn7)} is shown in Fig. 9 .
[0221] Example 7. Obtaining a recombinant baculovirus, R0333 {rBEV-8KC (OB2)}, in which the OB2 insertion site is loaded with an AAV8 packaging element expression cassette.
[0222] 1. Preparation of CmR-8KC(OB2)-ΔCC-DH10Bac competent cells
[0223] Similarly, using the AcMNPV genomic bacmid bMON14272 as a template, primers HAL(p15)-F (SEQ ID NO.40): 5'-ATGCATtaccatcgcatacaac-3' and HAL(p15)-R (SEQ ID NO.41): 5'-ACTAGTttaactgtttacataac-3' were designed to amplify the fragment HAL(p15) (412 bp) (the sequence is shown in SEQ ID NO.16); using the AcMNPV genomic bacmid bMON14272 as a template, primers HAR(cg30)-F (SEQ ID NO.42): 5'-Gcatgcttaatctacatttattgtaac-3' and HAR(cg30)-R (SEQ ID NO.43): 5'-GTTTAAACgaagacaacaacgc-3' were designed to amplify the fragment HAR(cg30) (458 bp) (the sequence is shown in SEQ ID NO.17);
[0224] The DNA fragments of HAL (p15) (412 bp), HAR (cg30) (458 bp), P1-FRT-CmR-P2 (1053 bp) and the packaging element expression cassette of AAV8 (sequence as shown in SEQ ID NO.14) were linearized by molecular cloning recombination with restriction enzyme cutting sites, and cloned on the vector plasmid pQB1064 to obtain the pQB1064-HAL (p15) -P1-FRT-CmR-P2-8KC-HAR (cg30) plasmid (SEQ ID NO.48, the vector sequence of SEQ ID NO.48 will clarify the actual sequence and position of 8KC (OB2) at the OB2 site). After linearization of the pQB1064-HAL(p15)-P1-FRT-CmR-P2-8KC-HAR(ORF91) plasmid, the DNA fragment HAL(p15)-P1-FRT-CmR-P2-8KC-HAR(ORF91) was recovered by gel recovery, and the DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac. The monoclonal bacterial solution of pKD46 / CmR-8KC(OB2)-ΔCC-DH10Bac was screened and identified. After culturing at 42°C to eliminate the pKD46 plasmid, the CmR-8KC(OB2)-ΔCC-DH10Bac competent cells were prepared by resistance plate screening.
[0225] 2 Obtaining recombinant baculovirus R0333 {rBEV-8KC (OB2)}
[0226] The CmR-8KC(OB2)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant Bacmid DNA, which was then transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0333{rBEV-8KC(OB2)}#P0 was obtained, which was transferred into the suspension Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected to obtain a higher titer of seed virus in the Sf9 cells. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored to obtain the recombinant baculovirus R0333{rBEV-8KC(OB2)}#P1. The genome diagram of R0333{rBEV-8KC(OB2)} is shown in the figure. Fig.10 .
[0227] Example 8. Obtaining a recombinant baculovirus containing the AAV8 packaging element expression cassette and Tn7 recombinant ITR-EGFP at the OB2 insertion site, R0334 {rBEV-8KC (OB2) -EGFP (Tn7)}
[0228] The cloning vector pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR (sequence as shown in SEQ ID NO.15, the vector sequence of SEQ ID NO.15 will clarify the actual sequence and position of EGFP (Tn7) at the Tn7 site. The actual sequence and position of 8KC (OB2) have been clarified in the previous example.) constructed in Example 4 was used to transform the pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR plasmid into the CmR-8KC (OB2)-ΔCC-DH10Bac competent cells prepared in Example 7, and the recombinant clones were screened by blue-white screening, and the recombinant Bacmid DNA was extracted by shaking. The Bacmid DNA was transfected into the host cell line for culture, and the recombinant baculovirus was obtained after 4 days of culture.
[0229] R0334{rBEV-8KC(OB2)-EGFP(Tn7)}#P0 was transferred into suspension Sf9 cells for 3 days. The recombinant baculovirus that replicated and proliferated further infected the Sf9 cells, resulting in a higher titer of seed virus. The partially packaged cell suspension was centrifuged at 3000rpm for 5min, and the supernatant was packaged and stored, which was the harvested recombinant baculovirus R0334{rBEV-8KC(OB2)-EGFP(Tn7)}#P1. The remaining packaged cell suspension was used to purify the recombinant adeno-associated virus R0334-AAV8-EGFP. The genome diagram of R0334{rBEV-8KC(OB2)-EGFP(Tn7)} is shown in the figure. Fig.11 .
[0230] Example 9. Obtaining a recombinant baculovirus loaded with ITR-EGFP at the OB3 insertion site, R0335{rBEV-8KC(OB3)-EGFP(Tn7)}
[0231] 1. Preparation of CmR-8KC(OB3)-ΔCC-DH10Bac competent cells
[0232] Since the GC content of the terminal sequences of the upstream and downstream homology arms of the OB3 site was extremely low, a biotechnology company was commissioned to synthesize the sequence HAL (prot) (478 bp) (sequence shown in SEQ ID NO.18); an outsourced biotechnology company was commissioned to synthesize HAR (pkip) (428 bp) (sequence shown in SEQ ID NO.19);
[0233] The linearized DNA fragments of HAL(prot) (478bp), HAR(pkip) (428bp), P1-FRT-CmR-P2 (1053bp) and the packaging element expression cassette of AAV8 (sequence as shown in SEQ ID NO.14) were cloned on the vector plasmid pQB1064 to obtain the pQB1064-HAL(prot)-P1-FRT-CmR-P2-8KC-HAR(pkip) plasmid (SEQ ID NO.49, the vector sequence of SEQ ID NO.49 will clarify the actual sequence and position of 8KC (OB3) at the OB3 site). After linearization of the pQB1064-HAL(prot)-P1-FRT-CmR-P2-8KC-HAR(pkip) plasmid, the DNA fragment HAL(prot)-P1-FRT-CmR-P2-8KC-HAR(pkip) was recovered by gel recovery, and the DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac. The monoclonal bacterial solution of pKD46 / CmR-8KC(OB3)-ΔCC-DH10Bac was screened and identified. After culturing at 42°C to eliminate the pKD46 plasmid, the CmR-8KC(OB3)-ΔCC-DH10Bac competent cells were prepared by resistance plate screening.
[0234] 2 Obtaining recombinant baculovirus R0335 {rBEV-8KC (OB3)}
[0235] The CmR-8KC(OB3)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant Bacmid DNA, which was then transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0335{rBEV-8KC(OB3)}#P0 was obtained, which was transferred into the suspension Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected to obtain a higher titer of seed virus in the Sf9 cells. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored to obtain the recombinant baculovirus R0335{rBEV-8KC(OB3)}#P1. The genome diagram of R0335{rBEV-8KC(OB3)} is shown in the figure. Fig.12 .
[0236] 3. Two baculovirus-infected host cells to package recombinant adeno-associated virus R0335-AAV8-EGFP
[0237] R0335{rBEV-8KC(OB3)}#P1 and R0004{rBEV-EGFP(Tn7)}#P1 were inoculated into suspension Sf9 cells at MOI 0.05 and cultured for 3 days. The viruses were collected and used to purify the recombinant adeno-associated virus R0335-AAV8-EGFP.
[0238] Example 10. Obtaining a recombinant baculovirus loaded with ITR-EGFP at the OB3 insertion site, R0336 {rBEV-ITR-EGFP (OB3)}, and two baculovirus-infected host cells to package recombinant adeno-associated virus R0336-AAV8-EGFP
[0239] 1. Preparation of CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac competent cells
[0240] The ITR-EGFP packaging element expression cassette (sequence as shown in SEQ ID NO.6) linearized DNA fragment obtained by enzyme digestion and gel recovery in Example 2 was used, and the HAL (prot) (478 bp), HAR (pkip) (428 bp), P1-FRT-CmR-P2 (1053 bp) and ITR-EGFP packaging element expression cassette (sequence as shown in SEQ ID NO.6) linearized DNA fragments were cloned on the vector plasmid pQB1064 to obtain pQB1064-HAL (prot) -P1-FRT-CmR-P2-ITR-EGFP-HAR (pkip) plasmid (SEQ ID NO.50, the vector sequence of SEQ ID NO.50 will clarify the actual sequence and position of EGFP (OB3) at the OB3 site). After linearization of the pQB1064-HAL(prot)-P1-FRT-CmR-P2-ITR-EGFP-HAR(pkip) plasmid, the DNA fragment HAL(prot)-P1-FRT-CmR-P2-ITR-EGFP-HAR(pkip) was obtained by gel recovery, and the DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac. The monoclonal bacterial solution of pKD46 / CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac was screened and identified. After culturing at 42°C to eliminate the pKD46 plasmid, the CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac competent cell was prepared by resistance plate screening.
[0241] 2 Obtaining recombinant baculovirus R0336 {rBEV-ITR-EGFP (OB3)}
[0242] The CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant Bacmid DNA, and the Bacmid DNA was transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0336{rBEV-ITR-EGFP(OB3)}#P0 was obtained, which was transferred into the suspension Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected to obtain a higher titer of seed virus in the Sf9 cells. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0336{rBEV-ITR-EGFP(OB3)}#P1. The genome diagram of R0336{rBEV-ITR-EGFP(OB3)} is shown in the figure. Fig.13 The fluorescence photos of cells of R0336{rBEV-ITR-EGFP(OB3)}#P1 were expanded to P7 at a fixed inoculation starting density and inoculation MOI. Fig.15 ; As shown in the figure, the expression of the target gene EGFP fluorescence inserted into the OB3 site remained stable in the P7 generation.
[0243] 3. Two baculovirus-infected host cells to package recombinant adeno-associated virus R0336-AAV8-EGFP
[0244] R0335{rBEV-8KC(OB3)}#P1 and R0336{rBEV-ITR-EGFP(OB3)}#P1 were inoculated into suspension Sf9 cells at MOI 0.05 and cultured for 3 days. The viruses were collected and used to purify the recombinant adeno-associated virus R0336-AAV8-EGFP.
[0245] Example 11. Obtaining a recombinant baculovirus with 8KC loaded at the OB1 insertion site and ITR-EGFP loaded at the OB2 insertion site, R0337 {rBEV-8KC (OB1)-ITR-EGFP (OB2)}.
[0246] 1. Preparation of GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac competent cells
[0247] The synthetic sequence FRT-pCAT-GmR (SEQ ID NO.51) was cloned with the pQB1064-HAL(prot)-P1-FRT-CmR-P2-ITR-EGFP-HAR(pkip) plasmid (SEQ ID NO.50, the vector sequence of SEQ ID NO.50 will clarify the actual sequence and position of EGFP (OB3) at the OB3 site) of Example 10 by molecular cloning recombination using restriction enzyme sites to obtain the pQB1064-HAL(prot)-P1-FRT-GmR-P2-ITR-EGFP-HAR(pkip) plasmid (SEQ ID NO.52)
[0248] The pQB1064-HAL(prot)-P1-FRT-GmR-P2-ITR-EGFP-HAR(pkip) plasmid was cloned with HAL(p15) (412 bp) and HAR(cg30) (458 bp) obtained in Example 6 by molecular cloning recombination using restriction enzyme sites to obtain the pQB1064-HAL(p15)-P1-FRT-GmR-P2-ITR-EGFP-HAR(cg30) plasmid (SEQ ID NO.53, SEQ ID The vector sequence of NO.53 will clarify the actual sequence and position of EGFP (OB2) at the OB2 site), and after linearizing the pQB1064-HAL (p15) -P1-FRT-GmR-P2-ITR-EGFP-HAR (cg30) plasmid, the DNA fragment HAL (p15) -P1-FRT-GmR-P2-ITR-EGFP-HAR (cg30) is obtained by gel recovery, and the DNA fragment is transformed into Example 1 to obtain The CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were screened and identified to obtain the monoclonal bacterial solution of pKD46 / GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac. After culturing at 42°C to eliminate the pKD46 plasmid, the GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were prepared by resistance plate screening.
[0249] 2 Obtaining recombinant baculovirus R0337 {rBEV-8KC (OB1)-ITR-EGFP (OB2)}
[0250] The GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant Bacmid DNA, which was then transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)}#P0 was obtained, which was transferred into the suspension Sf9 cells for culture for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected, resulting in the Sf9 cells obtaining a higher titer of seed virus. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)}#P1. The genome diagram of R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)} is shown in the figure. Fig.14The fluorescence photos of cells of R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)}#P1 were expanded to P7 at a fixed inoculation starting density and inoculation MOI. Fig.15 ; As shown in the figure, the expression of the target gene EGFP fluorescence inserted into the OB2 site remained stable in the P7 generation.
[0251] Example 12. The infection titer of the recombinant baculovirus was detected by the TCID50 method of indirect immunofluorescence based on the GP64 protein expressed by the recombinant virus.
[0252] The sf9 insect cells cultured in serum-free medium Sf-900II SFM were cultured to a live cell density of 1-6E+6 cells / mL and a cell viability of more than 95%. The cell suspension was diluted to a live cell density of 4.5E+5 cells / mL, and 100 μL of the cell suspension was used to plate Sf9 cells in 96-well plates. The plates were incubated at 27°C for 0.5-2 hours and then infected.
[0253] The samples to be tested were R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1, R0330{rBEV-8KC-EGFP(OB1)}#P1, and R033 1{rBEV-8KC(OB1)-EGFP(Tn7)}#P1, R0332{rBEV-8KC(OB1)}#P1, R0004{rBEV-EGFP(Tn7)}#P1, R0333{rBEV-8KC(OB2)}#P1, R0334{rBEV-8KC(OB2)-EGFP(Tn7)}#P1, R0335{rBEV-8KC(OB3)}#P1 and R0336{rBEV-ITR-EGFP(OB3)}#P1 seed viruses, all of which were prepared by taking 100μ1 seed virus stock solution and adding it to 900μl of Sf-900II SFM culture medium to make 10-1, and taking 100μ1 seed virus stock solution from 1mL of 10-1 and adding it to 900μl of Sf-900II SFM culture medium to make 10-1. The concentration in SFM is 10-2, and then gradient dilution is performed to 10-9. Each gradient of each virus is inoculated in a 96-well plate with Sf9 cells, 100 μL per well, and 8 replicate wells are inoculated for each gradient. After infection, the virus is incubated at 27°C for 96 hours, the supernatant is discarded, and the cell surface is washed once with 200 μL PBS (pH 7.2), the PBS is discarded, 150 μL anhydrous ethanol is added, and the virus is fixed at room temperature for 10-15 minutes. The anhydrous ethanol is discarded, and the virus is left at room temperature for 2-5 minutes to dry naturally. Add 200 μL PBS (pH 7.2) to each well to wash the cell surface once, discard the PBS, add 100 μL primary antibody working solution (Baculovirus Envelop gp64 monoclonal antibody diluted 1:500 with PBS), incubate at 37°C for 1 h, discard the primary antibody working solution, wash the plate 3 times with Wash Buffer (0.05% Tween-20 in PBS) adding 200 μL each time, wash the plate 1 minute with slight shaking during the washing process, wash twice with PBS in the same way, discard the washing solution, add 100 μL secondary antibody working solution (Goat anti-Mouse IgG (H+L) monoclonal antibody diluted 1:300 with PBS) to each well, incubate at 37°C for 1 h, discard the secondary antibody working solution, wash the plate 3 times with Wash Buffer (0.05% Tween-20 in PBS) adding 200 μL each time, wash the plate 1 minute with slight shaking during the washing process, wash twice with PBS in the same way, discard the washing solution, add 100 μL PBS, observe and determine the wells with red fluorescence positive cells under a fluorescence microscope, and mark them. The recombinant baculovirus infection titer is calculated according to the Reed-Muench method. The indirect immunofluorescence TCID50 infection titer results of various viruses are shown in Table 1:
[0254] Table 1
[0255]
[0256] Example 13. New method based on Gluc (OB1) expressed by recombinant virus to detect the infection titer of recombinant baculovirus
[0257] The sf9 insect cells cultured in serum-free medium Sf-900II SFM were cultured to a live cell density of 1-6E+6 cells / mL and a cell viability of more than 95%. The cell suspension was diluted to a live cell density of 4.5E+5 cells / mL, and 100 μL of the cell suspension was used to plate Sf9 cells in 96-well plates. The plates were incubated at 27°C for 0.5-2 hours and then infected.
[0258] The R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1 seed virus with a known titer of 1.311E+07TCID50 / mL was inoculated into suspended Sf9 cells at an MOI of 0.05 and cultured for 3 days before the virus was harvested. The partially packaged cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored to obtain the harvested recombinant baculovirus R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P2. The remaining sample was used to purify R0329-AAV8-EGFP.
[0259] R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1 was diluted to recombinant baculovirus standards with titers of 1.2E+7TCID50 / mL, 6E+6TCID50 / mL, 3E+6TCID50 / mL, 1.5E+6TCID50 / mL and 7.5E+5TCID50 / mL, and inoculated into 96-well plates with Sf9 cells, 100 μL per well, and 3 replicates were inoculated.
[0260] The sample R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P2 seed virus stock solution was inoculated into the same 96-well plate wells with Sf9 cells as the standard virus, 100 μL per well, and 3 replicates were inoculated; fresh culture medium Sf-900II SFM was used as a blank control, 100 μL per well, and 3 replicates were inoculated; the standard virus and the virus to be tested were infected with Sf9 cells for 2 hours, and the fresh culture medium was replaced, and the culture was continued for 4 hours. 50 μL of supernatant (without centrifugation) was taken from the 3 cell wells of each sample to a new 96-well black plate, and 50 μL of 1:100 luciferase kit substrate was added to each well, incubated for 5 minutes, and the chemiluminescence intensity was measured in a chemiluminescence detector. The average value of the obtained value was deducted from the average luciferase activity background value of the culture medium control as the actual luciferase activity value.
[0261] The logarithm of the virus infection titer of the standard was used as the abscissa, and the actual luciferase activity value was used as the ordinate to create a standard curve and a linear regression equation:
[0262] Y = a × logX-b;
[0263] X: virus infection titer, TCID50 / mL;
[0264] Y: luciferase activity value, RLU;
[0265] a, b: the slope and intercept of the linear regression equation respectively;
[0266] The actual luciferase activity value of the virus sample to be tested is substituted into the linear regression equation to calculate the virus infection titer of the virus sample to be tested.
[0267] Table 2. Results of the new recombinant baculovirus luciferase titration method
[0268]
[0269] The titer of the original virus R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1 was 1.311E+07TCID50 / mL, and the titer measured by the method of the present invention was 1.39E+7 / mL, which was within the expected range. In addition, the titer of the virus to be tested R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P2 was 8.10E+06 / mL. The R 2 =0.9845, the result is reliable. Fig.16 This is the correlation analysis between recombinant baculovirus luciferase activity and titer.
[0270] In the recombinant baculovirus expression system, the most widely used methods for determining the infection titer of recombinant baculovirus are the direct fluorescence of virus background expression and the TCID50 method of GP64 antibody immunoindirect fluorescence, as well as the flow detection method based on baculovirus GP64 fluorescent antibody. The TCID50 method of direct fluorescence of virus background expression is not applicable to recombinant baculovirus that does not express fluorescence and expresses the same fluorescence as the recombinant virus produced by the system. In addition, the cost of using antibodies using fluorescent antibodies is too high. The method based on the standard curve of the present application can detect the virus titer quickly, efficiently and at low cost.
[0271] Example 14. Purification of AAV and testing of electrophoresis gel silver staining
[0272] 10 mL of the initial mixed solution of the recombinant adeno-associated virus R0329-AAV8-EGFP collected in Example 1, the initial mixed solution of the recombinant adeno-associated virus R0330-AAV8-EGFP collected in Example 2, the initial mixed solution of the recombinant adeno-associated virus R0331-AAV8-EGFP collected in Example 4, the initial mixed solution of the recombinant adeno-associated virus R0334-AAV8-EGFP collected in Example 8, the initial mixed solution of the recombinant adeno-associated virus R0335-AAV8-EGFP collected in Example 9, and the initial mixed solution of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10 were taken out and centrifuged respectively. The cell precipitate and supernatant were harvested, and the cell precipitate and supernatant were purified respectively. The cells were repeatedly frozen and thawed for 3 times, and the lysate supernatant was collected by centrifugation at 5000rpm for 10min. The lysate supernatant was added to the original supernatant, 10% PEG was added for 2 hours at 4°C ice bath, and the harvested precipitate was resuspended with PBS, and nuclease (Benzonase) was added for 60min in a 37°C water bath, and the supernatant was collected by centrifugation at 5000rpm for 10min, and purified by iodixanol density gradient centrifugation (methods are shown in Aslanidi et al., 2009, Proc. Natl Acad. Sci. USA, 206: 5059-5064). The final purified finished virus was resuspended with 80μL PBS, and 10μL of the purified finished virus was run on SDS-PAGE gel for staining.
[0273] The results of the purified virus of each recombinant baculovirus system model are as follows: Fig.17 . Lanes 1, 2, 3, 4, 5, and 6 are, respectively, the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0329-AAV8-EGFP collected in Example 1, the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0330-AAV8-EGFP collected in Example 2, the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0331-AAV8-EGFP collected in Example 4, the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0334-AAV8-EGFP collected in Example 8, the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0335-AAV8-EGFP collected in Example 9, and the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10. The sample loading amount is 20 μL for all of them. The titer of the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10 is relatively low, and only faint shadows can be seen for VP1 and VP2.
[0274] Based on the above embodiments of the present application, it can be seen that the present application screened out new insertion sites OB1, OB2 and OB3 in the recombinant baculovirus (BEV) genome that can allow stable expression of exogenous genes, and loaded luciferase (Luciferase) reporter gene expression frames and necessary functional elements of recombinant adeno-associated virus at the new sites, so that the BEV of the recombinant baculovirus genome can be packaged at three sites for recombinant adeno-associated virus based on one, two or more component versions of the baculovirus system; and invented a new method for measuring the infection titer of recombinant baculovirus based on the Luciferase reporter gene expressed by the very early promoter. When measuring the titer of the recombinant baculovirus constructed according to the method of the present invention, the virus sample does not need to be diluted, and the virus titer is measured within 4 hours after the liquid is replaced 2 hours after the cells are infected. There is no need to observe cell pathology, fluorescence or staining, and the operation is simple, time-saving and cost-effective.
[0275] In summary, the present application is based on the concept of the conservative locus of recombinant baculovirus, and uses the point where the stop codon of the conservative locus is reversely overlapped, directly connected, or connected to the sequence to insert the foreign gene, thereby minimizing the disruption of the expression of the original known and unknown functional elements, and exploring and screening new recombinant baculovirus genome insertion sites that can stably carry foreign genes. The use of new insertion sites has obtained a recombinant baculovirus system with higher flexibility and compatibility; the infection titer determination method of the present application is more convenient, more accurate and low-cost.
[0276] SEQ ID NO.1:
[0277] Aacatgtataattgaaataaatatattatttaataaaatgttttttat.
[0278] SEQ ID NO.2:
[0279]
[0280] SEQ ID NO.3:
[0281]
[0282] SEQ ID No.4:
[0283] Cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct。
[0284] SEQ ID No.5:
[0285] Aggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagg。
[0286] SEQ ID NO.6:
[0287]
[0288] SEQ ID NO.7:
[0289] Gggtgtacaggtaacggccaattcaacgtgacgatgcgcacgtcctcgggtatgcatttgttaaaaaacacacagctcgctttaccaaacgaaagcaaaggtactaaatatggcgccattggctgatttgttattccaagataattacaaataaactgatccgtcgtggggtgataactggcaggtgtcagctttaaataatcttcaacg ttgttgtcgcgcaaaagtctgcattttacacgcgttgttaatcccacgacttttgcatgtaaaatcggatccaaatactgcagaatcgtgtctataatttctaat ggtaaacgtatgcgttttgctcgtgggcgctttgtaacgctcgacatcctaataacaactaacacaaaactaaaatgatactcaatatattgcttCCCGGGGGGA。
[0290] SEQ ID NO.8:
[0291] ACATGcatgctctcaacacactcgctatttggaacataatcatatcgtctcagtagctcaaggtagagcgtagcgctctggatcgtatagatcttgctaaggttgtgagttcaagtctcgcctgagatattaaaaaactttgtaattttaaaaattttattttataatatacaattaaaaaactatacaattttttattattacattaataatgatacaatttttattattacatttaatattgtctattacggtttctaatcatacagtacaaaaataaaatcacaattaataataattacaaagttaactacatgaccaaacatgaacgaagtcaatttagcggccaattcgccttcagccatggaagtgatgtcgctcagactggtgccgacgccgccaaacttggtgttctccagtttaaacaaagct。
[0292] SEQ ID NO.9:
[0293]
[0294] SEQ ID NO.10:
[0295] ccaAtgcattcatacgctatagatccggtgacggccatcgaatgtataaactacatgaacaacaacgtgcaaagcgtcacgttgaccgacacttgccccgcaattgaattgcggtttcagcaattttttgatccaccgctacagcagagcaattacatgaccgtgtccgtggacgggtatgtcgtgctcgacaccgagttgagatacgtcaaatataaatggatgccaacaaccgagttagagtatgacgccgtgaataagtcgtttaacacactcaatgggccattgaacggtctcatgattttaaccgacttgccggagttactgcacgaaaacatttacgaatgtgtaatcacggacacgacaataaacgtgttgaaacatcgtcgcgaccgaatcgtgccaaattaacccgggggt。
[0296] SEQ ID NO.11:
[0297] acatGcatgcttaaagcacgttaagcggatacaacgggcagtccgagctgttaaagtcaatacaaccatcgttaacaaacgaatacgcattgttgtgacagctgaggatataaaaaggaatagagaagtaattgcaatgaaatatcccgttacaattccacggcacagcgtatgttgctcgagttctatcagttgcacacaacggcctaagaaaatttattaatgcttcatttgtatctatattagaaggataatacataggttcgcccaaaggactgggagaaggcggcggcgaaggtgtaggtgtaggaggaataggagaaggtggag gtttaaacaaagct。
[0298] SEQ ID NO.12:
[0299]
[0300] SEQ ID NO.13:
[0301]
[0302] SEQ ID NO.14:
[0303]
[0304] SEQ ID NO.15:
[0305]
[0306] SEQ ID NO.16:
[0307] ATGCATtaccatcgcatacaacattatgaatacaaggggttgtgttaataataataaaatgatatttatgaatgctttgggcttgcaacctcaaagtaaattgaaaattattgcacataaaatactagaaaaatgtaaacgtgacgcgtacacgcgtttcaagggcgtaaaggcgatcaagaatgaactaaaaacatacaatcttacgttgcaacaatacaacgaggcgctcaatcagtgcgctttaaacgatagccgatggcgcgacacaaataattggcatcacgatattgaagaaggtgtgaaaataaacaagagacatatatatagagttaattttaattctaaaacccaagaaattgaagaatattattacattaaagtagaatgttatgtaaacagttaaACTAGT。
[0308] SEQ ID NO.17:
[0309] Gcatgcttaatctacatttattgtaacatttgtggtaatagtggcgttggttatacatttatatgattgtaatgttgtgtactcgttttgtaataaatttttgtgtttaatcaattcaatatttttatttgataaaaccttattttcgctactcaatttggcgtttttagacgcaagttttgcgtaatcgtcattgagcgattttagcgccttttcagttgtaattcgt ttcagttgcaattctttaaaagatttatgcatgttgttgtagtcgcttttaattttgtctaacttttcttgcatagaaacgcttgtttgttgtaatttgtctaaatctaattgttgtttaatgttgagctgcgtttgttcggcaatgtctacctgtagttttttagtatcgcttgtgcttcagacagcatagtgtcgtcggcatttgcgttgttgtcttcgtttaaac。
[0310] SEQ ID NO.18:478bp
[0311] AtgcatCGCGCGCGacattaaagattacacatcgacgccccatcattttttccatcagtctaaaatttacaccaacagcgcggcgcccgacgaagactcgcaagacgacagtaataccaccgtggtaattatcgctattgtcgctgcaatgatcctattctgtggattattgttatttttgttttgctgtataaaaaaacggtgtcatcaatcaaataacgtggttgtgcaatacaaaaataacaatgaatttgtcacaatttgcaataatttagaagacaatcgagcatacattaatttacctaatgaatacgatagcgatgatatgccaaaaccattgtacccttttacttggctttaatgatgatttgttaaaagatgataaacctgtgttgtaccctatgattagaaagaataaaataaaacatgtataattgaaataaatatattatttaataaaatgttttttatactagt。
[0312] SEQ ID NO.19:
[0313] Gcatgcaatgttttttatttatatactattttctattacatattccaatgcacacaaatgtttaaatggctatcagttttaattttactaattcgtctaaacaaaaattattcacttgctgtttttcatccatttgacatatggcgtttataaataattcgctgtgttttatgaacgaatcgtaaaccgctgcctgggccttcagcacggtcggc gcattgtatttttgggtaaagtacgcaatatttttagtcaaacacagagattttaaatctttttcatttatatccaagtcggaacaatcgtatacaaaatctagctt ttcactttcgggcgcgcccagatactggtttacgagttcgagctgctccacttggcctttgatatcggccgctatgcacaacattttgtcgattgcagtgtttaaac。
[0314] SEQ ID NO.44 (5644 bp)
[0315]
[0316]
[0317] 2467..2778=312 bp: HAR (ORF91) homology arm; 4913..5311=399 bp: HAL (lef4) homology arm; the region between taa and tta marked in bold font: 2782..4909=2128 bp inserted foreign gene.
[0318] SEQ ID NO.45 (12097 bp)
[0319]
[0320] SEQ ID NO.46 (12716 bp)
[0321]
[0322]
[0323]
[0324]
[0325] 2467..2778=312bp: HAR (ORF91) homology arm; _11985..12383=399bp: HAL (lef4) homology arm; the region between taa and tta marked in bold: 2782..11981=9200bp inserted foreign gene; 5093..7602=2510bpp10-Cap8-PA, of which 5252..7468=2217bp Cap8.
[0326] SEQ ID NO.47 (9720 bp)
[0327]
[0328]
[0329]
[0330] 2467..2778=312bp: HAR (ORF91) homology arm; 8989..9387=399bp: HAL (lef4) homology arm; the region between taa and tta marked in bold font: 2782..8985=6204bp inserted foreign gene.
[0331] SEQ ID NO.48 (9613 bp)
[0332]
[0333]
[0334] 2462..2902=441bp: HAR (cg30) homology arm; 8876..9272=397bp: HAL (p15) homology arm; the region between taa and tta marked in bold font: 2906..8872=5967bp of the inserted foreign gene.
[0335] SEQ ID NO.49 (9629 bp)
[0336]
[0337]
[0338] 2462..2860=399bp: HAR (pkip) homology arm; _8882..9288=407bp: HAL (port) homology arm; the region between taa and tta marked in bold font includes: 2864..8830=5967bp of inserted foreign gene, and 8831..8878=48bp of non-coding 48bp.
[0339] SEQ ID NO.50 (7770 bp)
[0340]
[0341]
[0342] 342..748=407bp: HAL (prot) homology arm; 4911..5309=399bp: HAR (pkip) homology arm; the region between taa and tta marked in bold font: 752..4907=4156bp inserted foreign gene.
[0343] SEQ ID NO.51 (930 bp)
[0344] Actagtaaatcagtcacaccaaggcttcaataaggaacacacaagcaccatggtccatcatcaccaccatcactccgcgggatccctgcagaagcttatgggaattagccatggtccatatgaatatcctccttagttcctattccgaagttcctattctctagaaagtataggaacttcggcgcgcctacctgtgacggaagatcacttcgcagaataaataaatcctggtgtccctgttgataccgggaagccctgggccaacttttggcgaaaatgagacgttgatcggcacgtaagaggttccaactttcaccataatgaaataagatcactaccgggcgtattttttgagttgtcgagattttcaggagctaaggaagctaaaatgttacgcagcagcaacgatgttacgcagcagggcagtcgccctaaaacaaagttaggtggctcaagtatgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgcgggctgctcttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgcccaggtttgagcagccgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggaggcagggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaaatttaaat。
[0345] SEQ ID NO.52(7636bp)
[0346]
[0347]
[0348]
[0349] 342..748=407bp: HAL (prot) homology arm; 4777..5175=399bp: HAR (pkip) homology arm; the region between taa and tta marked in bold font: 752..4773=4022bp inserted foreign gene.
[0350] SEQ ID NO.53 (7668 bp)
[0351]
[0352] 2462..2902=441 bp: HAR (cg30) homology arm sequence; 6931..7327=397 bp: HAL (p15) homology arm sequence; the region between taa and tta marked in bold font: 2906..6927=4022 bp inserted foreign gene sequence.
[0353] SEQ ID NO.54 (2501 bp)
[0354]
[0355] SEQ ID NO.55(2465bp)
[0356]
[0357] SEQ ID NO.56(2501bp)
[0358]
[0359] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0360] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solution of the present application in detail, but it cannot be understood as a limitation on the scope of protection of the patent application. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several deformations and improvements can be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, the technicians in this field can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by the technicians in this field through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the content of the attached claims, and the description and drawings can be used to explain the content of the claims.
Claims
1. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises: a nucleic acid fragment 1, a nucleic acid fragment 2 and an exogenous gene expression frame for expressing an exogenous fragment located between the nucleic acid fragment 1 and the nucleic acid fragment 2; The complementary fragments of the nucleic acid fragment 1 and the nucleic acid fragment 2 are a tail-to-tail gene pair; The nucleic acid fragment 1 and the nucleic acid fragment 2 are connected to a non-coding region, the 5' end of the non-coding region is taa and the 3' end is tta, and the exogenous fragment is inserted between taa and tta; The sequence of the non-coding region is taatta, and the exogenous gene expression frame is inserted between taa and tta; The tail-to-tail gene pair is the p15 gene and the cg30 gene, and the corresponding insertion site is recorded as the OB2 site.
2. The nucleic acid molecule according to claim 1, characterized in that The tail-to-tail gene pair is from a baculovirus.
3. The nucleic acid molecule according to claim 1, characterized in that The exogenous fragments include one or more of a selection marker gene and a target gene.
4. The nucleic acid molecule according to claim 3, characterized in that The exogenous gene expression cassette satisfies one or more of the following conditions 1) and 2): 1) the exogenous gene expression frame includes a promoter regulating the selection marker gene including a baculovirus very early promoter; and, 2) The exogenous gene expression frame includes a promoter that regulates the target gene, including a P10 promoter or a PH promoter.
5. The nucleic acid molecule according to claim 3, characterized in that The exogenous fragment satisfies one or more of the following conditions (A) and (B): (A) the selection marker gene comprises one or more of a luciferase gene, a neomycin resistance gene, a hygromycin phosphotransferase gene, a dihydrofolate reductase gene, a thymidine kinase gene, a glutamine synthetase gene, an asparagine synthetase gene, a tryptophan synthetase gene, a histidinol dehydrogenase gene, an aminoglycoside phosphotransferase gene, and a tryptophan synthetase gene; and, (B) The target gene encodes one or more of an antibody, a polypeptide, an enzyme, a hormone, a growth factor and a protein receptor.
6. The nucleic acid molecule according to any one of claims 1 to 5, characterized in that The sequence of the nucleic acid molecule is shown in SEQ ID NO.48, 2903 bp to 8875 bp or in SEQ ID NO.52, 749 bp to 4776 bp.
7. A recombinant plasmid, characterized in that The recombinant plasmid comprises the nucleic acid molecule according to any one of claims 1 to 6.
8. A recombinant baculovirus, characterized in that The genome of the recombinant baculovirus comprises the nucleic acid molecule according to any one of claims 5 to 6.
9. The recombinant baculovirus according to claim 8, characterized in that The recombinant baculovirus satisfies one or more of the following conditions A) and B): A) the recombinant baculovirus is Spodoptera californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudococcidae multiple nucleocapsid nuclear polyhedrosis virus, Gypsy moth multiple nucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multiple nucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus or Spodoptera litura nuclear polyhedrosis virus; and, B) The foreign gene expression cassette defined in any one of claims 1 to 6 is inserted into other gene loci of the genome of the recombinant baculovirus.
10. The recombinant baculovirus according to claim 9, characterized in that The selection marker gene is inserted into any one of the OB1 site, the OB2 site and the OB3 site; The lef4 gene and the orf91 gene form a tail-to-tail gene pair, and the lef4 gene and the orf91 gene are connected by the noncoding region taatta, and the position between taa and tta is recorded as the OB1 site; The env-prot gene and the pkip gene form a tail-to-tail gene pair, and the env-prot gene and the pkip gene are connected via the non-coding region shown in SEQ ID NO.1, and any site in the non-coding region shown in SEQ ID NO.1 is recorded as the OB3 site.
11. The method for constructing a recombinant baculovirus according to any one of claims 8 to 10, characterized in that: The construction method comprises the following steps: causing homologous recombination between the donor plasmid and the baculovirus genome, thereby constructing a recombinant baculovirus; The donor plasmid comprises a nucleic acid fragment consisting of the nucleic acid molecule according to any one of claims 1 to 6.
12. The method for constructing a recombinant baculovirus according to claim 11, characterized in that: The recombinase used for homologous recombination is RED recombinase, Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.
13. The method for constructing a recombinant baculovirus according to any one of claims 11 to 12, characterized in that: The donor plasmid includes a shuttle plasmid.
14. An adeno-associated virus packaging vector system, characterized in that: It comprises essential elements for AAV packaging, which include one or more of Cap gene, Rep gene and ITR gene; the essential elements for AAV packaging are located in the same or different nucleic acid molecules according to any one of claims 1 to 6.
15. A method for producing an expression product of an exogenous fragment, characterized in that: The production method comprises the following steps: The recombinant baculovirus according to any one of claims 8 to 10 is used to infect host cells and then cultured, and the expression product of the exogenous fragment is separated from the obtained culture product.
16. The method for producing the expression product of the exogenous fragment according to claim 15, characterized in that: Such host cells include insect cell lines.
17. The method for producing the expression product of the exogenous fragment according to claim 16, characterized in that: The insect cell lines include Lepidoptera insect cell lines.
18. The method for producing the expression product of the exogenous fragment according to any one of claims 15 to 17, characterized in that: The production method further comprises the step of detecting the titer of the obtained recombinant baculovirus; The titer was detected using the standard curve method, which includes the following steps: Providing a standard curve, wherein the standard curve reflects the linear relationship between the luciferase activity value and the virus titer value; and, Detecting the activity value of luciferase expressed by the luciferin gene in the recombinant baculovirus to be tested, substituting it into the standard curve, and calculating the virus titer value of the recombinant baculovirus to be tested; The activity value of the luciferase = the luminescence intensity value generated by the luciferase expressed by the recombinant baculovirus - the luminescence intensity value of the virus-free control substance.
19. A method for producing a recombinant adeno-associated virus, characterized in that: The production method adopts the adeno-associated virus packaging vector system described in claim 14.
